

1 **Distinct disease mutations in DNMT3A result in a spectrum of behavioral, epigenetic, and**
2 **transcriptional deficits**

3 Diana C. Beard¹, Xiyun Zhang¹, Dennis Y. Wu¹, Jenna R. Martin¹, Nicole Hamagami¹, Raylynn
4 G. Swift^{2,3}, Katherine B. McCullough^{2,3}, Xia Ge^{4,8}, Austin Bell-Hensley^{5,6}, Hongjun Zheng⁶,
5 Austin B. Lawrence⁷, Cheryl A. Hill⁷, Thomas Papouin¹, Audrey McAlinden⁶, Joel R. Garbow^{4,8},
6 Joseph D. Dougherty^{2,3,8}, Susan E. Maloney^{2,8}, Harrison W. Gabel^{1,8,*}

7 ¹Department of Neuroscience, Washington University School of Medicine, St. Louis, MO 63110,
8 USA

9 ²Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110,
10 USA

11 ³Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA

12 ⁴Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110,
13 USA

14 ⁵Department of Biomedical Engineering, Washington University, St. Louis, MO 63110, USA

15 ⁶Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, MO
16 63110, USA

17 ⁷Department of Pathology and Anatomical Science, University of Missouri School of Medicine,
18 Columbia, MO 65212, USA

19 ⁸Intellectual and Developmental Disabilities Research Center, Washington University School of
20 Medicine, St. Louis, MO 63110, USA.

21 *Email: gabelh@wustl.edu

22
23 **Abstract**

24 Phenotypic heterogeneity is a common feature of monogenic neurodevelopmental disorders
25 that can arise from differential severity of missense variants underlying disease, but how distinct
26 alleles impact molecular mechanisms to drive variable disease presentation is not well
27 understood. Here, we investigate missense mutations in the DNA methyltransferase DNMT3A
28 associated with variable overgrowth, intellectual disability, and autism, to uncover molecular
29 correlates of phenotypic heterogeneity in neurodevelopmental disease. We generate a
30 DNMT3A P900L/+ mouse model mimicking a disease mutation with mild-to-moderate severity
31 and compare phenotypic and epigenomic effects with a severe R878H mutation. We show that
32 the P900L mutation leads to disease-relevant overgrowth, obesity, and social deficits shared
33 across DNMT3A disorder models, while the R878H mutation causes more extensive
34 epigenomic disruption leading to differential dysregulation of enhancers elements. We identify
35 distinct gene sets disrupted in each mutant which may contribute to mild or severe disease, and
36 detect shared transcriptomic disruption that likely drives common phenotypes across affected
37 individuals. Finally, we demonstrate that core gene dysregulation detected in DNMT3A mutant
38 mice overlaps effects in other developmental disorder models, highlighting the importance of
39 DNMT3A-deposited methylation in neurodevelopment. Together, these findings define central

40 drivers of DNMT3A disorders and illustrate how variable disruption of transcriptional
41 mechanisms can drive the spectrum of phenotypes in neurodevelopmental disease.

42

43 **Introduction**

44 As clinical sequencing becomes widely implemented and genetic studies of disease
45 increase in scope, an expanding number of causative variants are identified in each individual
46 disease gene. A subset of genes associated with phenotypically heterogeneous disorders such
47 as intellectual disability and autism spectrum disorder (ASD) are primarily associated with
48 missense mutations rather than simple truncating or loss of function mutations (Coe et al., 2019;
49 Satterstrom et al., 2020; Wang et al., 2020). In these missense-mediated disorders, studies of
50 multiple disease-causing alleles are important to establish phenotypes and molecular deficits
51 that are core to all disease-associated alleles and therefore central to the disease. Isogenic
52 animal models provide a powerful tool for understanding genotype-phenotype relationships,
53 especially when clinical populations are small, as they minimize confounding differences from
54 environmental factors and genetic background. Phenotypic heterogeneity and molecular
55 differences between variants can be used to identify potential mechanisms driving the diversity
56 of clinical presentation, while shared effects across models can define core pathways affected
57 and provide targets for candidate therapeutic testing.

58 DNA methyltransferase 3A (DNMT3A)-associated neurodevelopmental disorders are an
59 example in which it is critical to study molecular and phenotypic heterogeneity driven by a
60 diversity of missense mutations. Heterozygous mutations within *DNMT3A* are associated with
61 Tatton-Brown Rahman Syndrome (TBRS), an overgrowth and intellectual disability disorder
62 typified by macrocephaly, a distinct facial gestalt, obesity, and comorbid ASD (Tatton-Brown et
63 al., 2014, 2018). Similar to many syndromic neurodevelopmental disorder-associated genes,
64 DNMT3A mutations have also been identified in cohorts of individuals with a primary diagnosis
65 of ASD (Plummer et al., 2016; Sanders et al., 2012; Satterstrom et al., 2020). Disease
66 mutations in DNMT3A are frequently missense mutations, with truncating variants or gene
67 deletions underrepresented compared to chance estimates (Y. H. Huang et al., 2022; Tatton-
68 Brown et al., 2018). Missense mutations generally occur within the three canonical protein
69 domains of DNMT3A, and *in vitro* studies have demonstrated that mutations disrupt protein
70 function through a variety of mechanisms such as altering the ability to interact with modified
71 histones, causing loss of nuclear localization, abrogating the catalytic activity of the
72 methyltransferase domain, or destabilizing the protein (Christian et al., 2020; Y. H. Huang et al.,
73 2022; Lue et al., 2022). Through these mechanisms, diverse mutations may lead to differing

74 degrees of loss of function; however, it remains unclear to what extent these mutations result in
75 differential phenotypes *in vivo*.

76 Disease-associated disruption of DNMT3A likely impacts multiple aspects of nervous
77 system development and function. DNMT3A is expressed both embryonically and postnatally
78 and contributes to important developmental processes including genomic imprinting and
79 maturation of the nervous system (Kaneda et al., 2004; Okano et al., 1999; Stroud et al., 2017).
80 DNMT3A spikes in expression in postnatal neurons (between 1-3 weeks old in mice) (Feng et
81 al., 2005; Lister et al., 2013) during which it establishes uniquely high levels of non-CpG
82 methylation in neurons relative to other somatic cell types (Gabel et al., 2015; J. U. Guo et al.,
83 2014; Lister et al., 2013; Nguyen et al., 2007). This methylation, predominantly at CA
84 dinucleotides (mCA), is highly sensitive to the expression and activity levels of DNMT3A. For
85 example, heterozygous loss of DNMT3A leads to a 50% reduction in mCA genome-wide, while
86 modest overexpression of DNMT3A upon loss of microRNA regulation leads to excess
87 deposition of this mark (Christian et al., 2020; Swahari et al., 2021). A major function of mCA is
88 to recruit the methyl-binding protein MeCP2 to further regulate transcription through the activity
89 of enhancers (Boxer et al., 2020; Clemens et al., 2019). This transcriptional regulation occurs
90 broadly across the genome, tuning expression of large numbers of genes to allow neurons to
91 dynamically respond to activity and maintain cell-type-specific gene expression (Gabel et al.,
92 2015; Mo et al., 2015; Stroud et al., 2017).

93 Mouse models of DNMT3A disorders have established key effects associated with
94 pathology in the human disorder, but DNMT3A missense alleles have not been systematically
95 assessed in the brain. Analysis of DNMT3A heterozygous knockout (KO) mice has detected
96 growth and behavioral deficits that mirror aspects of human disease, with underlying alterations
97 in neuronal DNA methylation hypothesized to drive these effects (Christian et al., 2020; Tovy et
98 al., 2022). In addition, recent characterization of a mouse model of the R882H mutation
99 (DNMT3A^{R878H/+} mice) has demonstrated more severe behavioral disruption in comparison to the
100 heterozygous KO (Christian et al., 2020; Smith et al., 2021). However, studies of the R882H
101 mutation in acute myeloid leukemia suggest this mutation results in dominant negative effects
102 not observed for other mutations (Emperle et al., 2018; Russler-Germain et al., 2014; Smith et
103 al., 2021). Furthermore, the impact of the R882H mutation on neuronal DNA methylation has
104 not been assessed, and no model representing the majority of “typical” missense mutations
105 causing partial loss of function has been systematically analyzed *in vivo*. Therefore, core deficits
106 shared by the majority of disease-associated DNMT3A missense mutations remain undefined,
107 and the molecular underpinnings driving a spectrum of severity have not been assessed.

108 In this study, we addressed these gaps in knowledge by generating and characterizing a
109 mouse model of DNMT3A P904L mutation. Using these mice, which model a class of missense
110 mutations partially disrupting the methyltransferase activity of DNMT3A (Christian et al., 2020;
111 Tatton-Brown et al., 2018), we defined core deficits that are observed across DNMT3A models,
112 including overgrowth, obesity, social alterations, and reductions of neuronal DNA methylation.
113 We compared this model to a model of R882H mutation to identify distinct phenotypic,
114 epigenomic, and transcriptional effects of these two DNMT3A missense mutations *in vivo* and
115 observed more dramatic impacts on enhancer activity linked to increased phenotype severity in
116 the R882H model. Finally, we leverage these datasets to establish common molecular pathways
117 and etiology shared within DNMT3A models and use these core effects to explore convergent
118 molecular mechanisms potentially contributing to nervous system disruption across related
119 neurodevelopmental disorders.

120

121 **Results**

122 **P900L heterozygous mutant mice exhibit obesity and bone length overgrowth consistent** 123 **with other DNMT3A models**

124 To investigate the range of effects caused by missense mutations in DNMT3A and
125 characterize a “typical” mutation, we used CRISPR/Cas9 technology to generate a constitutive
126 DNMT3A P900L/+ (P900L) mutant mouse mimicking the recurrent human P904L mutation (see
127 methods). Sanger sequencing confirmed the correct heterozygous mutation (Supplemental
128 Figure 1A-B). This mutation has been shown to have robust loss of function effects when
129 characterized *in vitro* (Christian et al., 2020), and P900L mutants did not display severe
130 changes in general health (Supplemental Figure 1C). RT-qPCR of transcript levels of DNMT3A
131 P900L mice showed no detectable differences, however a subtle reduction in protein expression
132 was observed by western blot (Supplemental Figure 1D). This mild reduction in protein
133 expression indicates that though the mutant protein is expressed, a subset of effects may be
134 caused by this reduction in overall DNMT3A levels. With this model in hand, we next assessed
135 phenotypic differences caused by the P900L mutation.

136 Patients with DNMT3A mutations exhibit overgrowth (defined as being +2 standard
137 deviations from mean height), macrocephaly, and a distinctive facial gestalt, therefore we
138 measured homologous morphological changes in the P900L model to determine if these
139 mutants displayed similar overgrowth phenotypes. Human height is well correlated with leg
140 bone length (Duyar & Pelin, 2003), therefore we used digital x-ray imaging to measure femur
141 length and found that P900L femurs were significantly longer than WT littermates (Figure 1A-B).

142 We examined changes in skull morphology for macrocephaly using μ CT imaging and found no
143 overall increase in skull size, with few very subtle changes in distances between Euclidian
144 landmarks on the skull (Figure 1C-D). This indicates that the P900L model exhibits significant
145 changes in long bone length, without overall changes in skull size or shape.

146 Obesity is an emerging phenotype in the clinical TBRS population, and it has the
147 potential to impact many aspects of health for patients and families. To examine if an obesity
148 phenotype exists in the P900L model, we measured body weight and used EchoMRI to
149 measure body mass content in adult animals. P900L mutants displayed trends towards
150 increased body weight at 30-35 weeks and a significant increase in fat mass with no change in
151 lean mass, indicating that these animals have an obesity phenotype (Figure 1E-G). High fat
152 diets can exacerbate progressive weight gain effects (Smith et al., 2021) therefore we next
153 measured weight gain over time in animals on a high fat diet and found that there was a
154 significant increase in weight gain in the P900L animals compared to their WT littermates
155 (Figure 1H). Notably, this increase in body weight does not appear to be driven by an increase
156 in food consumption (Figure 1I). Thus, this new mutant model exhibits a progressive obesity
157 phenotype that may be driven by metabolic or cellular changes, rather than a difference in
158 feeding behavior.

159 These findings indicate that the P900L mutant has increases in long bone length and
160 body fat, suggesting that DNMT3A-associated overgrowth and obesity is consistent across
161 multiple mutations and can be studied using mouse models (Christian et al., 2020; Smith et al.,
162 2021; Tovy, Reyes, et al., 2022). In further agreement with published models, the P900L has no
163 dramatic differences in skull size or shape, suggesting that DNMT3A mouse models may not be
164 ideal for investigating TBRS-associated cranial overgrowth or facial structure. In contrast, the
165 existence of a reproducible increase in long bone length and body fat across this and other
166 mouse models indicates conserved DNMT3A-dependent processes affecting body fat and
167 skeletal development.

168

169 **DNMT3A mutant mice have decreased brain volume**

170 Macrocephaly is a common phenotype in TBRS, and other structural brain changes such
171 as ventriculomegaly and Chiari malformation have been observed (Tatton-Brown et al., 2014,
172 2018); however, brain size and structure in mice have yet to be investigated. We therefore
173 interrogated whether brain size or structure are affected in P900L adult mice using anatomic
174 magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI). No gross structural
175 changes were detected, and surprisingly, P900L mutant mice exhibited decreased whole brain

176 volumes (Figure 2A-B). We also observed trends towards reduced volume of the corpus
177 callosum that were proportional to changes in whole brain volume (Figure 2C-D) and found a
178 subtle but significant decrease in mean corpus callosum fractional anisotropy (FA) in the P900L
179 mutant (Figure 2E) indicating potential changes in white-matter tract integrity or organization.
180 P900L mutants also exhibited reduced cortical thickness across multiple cortical regions (Figure
181 2F-G). No significant differences in ventricular volume were detected (Figure 2H-I). Together
182 this phenotype contrasts with clinical data but suggests fundamental developmental processes
183 impacting brain size are disrupted by DNMT3A mutation in mice.

184 Because brain volume has not been previously investigated in DNMT3A mutant mice,
185 we repeated MRI imaging and volumetric analyses in DNMT3A^{R878H/+} (R878H) mice mimicking
186 the severe R882H mutation (Smith et al., 2021). Consistent with the P900L mutant, R878H
187 mutants showed a significant reduction in brain volume (Figure 2J), though there were no
188 significant changes in corpus callosum size or FA (Figure 2K-L) suggesting that white-matter
189 effects observed in the P900L mutants may be allele-specific. However, R878H mutants did
190 have significantly reduced ventricular volume and cortical thickness (Figure 2M-N), which likely
191 contributes to the overall reduction in brain volume. These data demonstrate that reduced brain
192 volume is a shared phenotype in DNMT3A mutant mice.

193 Given that DNMT3A has critical roles both embryonically (Kaneda et al., 2004; Okano et
194 al., 1999) and in early postnatal development (Lavery et al., 2020; Stroud et al., 2017), we next
195 assessed if onset of brain volume phenotypes occurs during early development or arises
196 progressively. This is especially important because previous studies have demonstrated
197 transcriptional overlap between DNMT3A and MeCP2 disorders, and MeCP2 mutants have
198 progressive decrease in brain volume which may be phenocopied in DNMT3A mutants (Akaba
199 et al., 2022; Allemang-Grand et al., 2017; Christian et al., 2020). We therefore imaged DNMT3A
200 mutant mice early in postnatal development, after any embryonic actions of DNMT3A and
201 before postnatal DNMT3A or MeCP2 are highly expressed. MRI analysis at P10 found no
202 evidence of altered brain size in P900L or R878H mutants (Figure 2O-P). Because the
203 disruption of brain volume occurs between P10 and adulthood in DNMT3A mutants, these
204 results suggest that reduced brain volume may be due to deficits in postnatal maturation or
205 survival rather than generation of neural cells.

206

207 **P900L mutants have altered social behavior and tactile sensitivity without changes in**
208 **activity, anxiety-like behaviors, or learning and memory**

209 Like numerous other syndromes associated with intellectual disability and ASD,
210 DNMT3A disorders are typified by variable behavioral deficits and there is limited understanding
211 of the molecular drivers of this diversity. To begin to define the shared and distinct cognitive
212 phenotypes, we first focused on domains of behavior previously disrupted in other models of
213 DNMT3A disorders, including activity, exploration, and anxiety-like behaviors (Christian et al.,
214 2020; Nguyen et al., 2007; Smith et al., 2021). We measured activity and natural digging
215 behaviors using an open field assay and marble burying assay, respectively. We found that
216 P900L mutants traveled similar distances compared to WT littermates (Figure 3A) and had no
217 differences in digging behavior (Figure 3B). No motor phenotypes were observed using
218 continuous or accelerating rotarod assays (Supplemental Figure 2A-B), and mutant mice
219 showed no differences in coordination or broad sensorimotor measures (Supplemental Figure
220 2C-H). To assess anxiety-like behaviors, we measured the time in the center of an open field
221 and the time in open arms of an elevated plus maze and found that P900L mutants showed no
222 significant differences in either of these assays (Figure 3C-D). These results indicate that
223 exploration, motor, and anxiety phenotypes are not shared across all DNMT3A models.

224 Intellectual disability is a central phenotype used for clinical diagnosis of TBRS that may
225 be variably present in individuals identified with DNMT3A mutations through studies of ASD. We
226 next examined whether the P900L mutant displayed deficits in the conditioned fear and Morris
227 water maze assays to assess aversive associative memory and spatial learning and memory,
228 respectively. In the conditioned fear assay, the P900L mutants displayed normal responses to
229 aversive stimulus presentation, and normal contextual and cued fear memory (Figure 3E-F;
230 Supplemental Figure 2I). P900L mutants also showed normal spatial learning in the Morris
231 water maze assay, as exhibited by mutants learning the location of a visually cued platform and
232 recalling the location of a hidden platform, following a slight difference upon initial task exposure
233 (Figure 3G-H). When the hidden platform was removed, mutants and WT mice spent similar
234 times investigating each quadrant of the maze with similar number of entries into the zone
235 where the platform was previously located (Figure 3I-J). Notably, the absence of robust learning
236 and memory deficits in the P900L mutation appears to mirror individuals with the homologous
237 human P904L mutation that do not have intellectual disability diagnoses (Sanders et al., 2015).

238 Because mutations in DNMT3A are not only associated with intellectual disability but are
239 also identified in individuals with a primary diagnosis of ASD (Sanders et al., 2012; Satterstrom
240 et al., 2020), we next assessed common phenotypes displayed in mice carrying mutations in
241 autism-associated genes (Chen et al., 2021; Han et al., 2020). In a three-chamber social
242 approach assay, the P900L mutants and WT littermates showed similar preferences for

243 exploring a conspecific rather than an object, and for exploring a novel conspecific rather than a
244 familiar mouse, with no change in overall distance traveled (Figure 3K; Supplemental Figure 2J)
245 suggesting that mutants have no change in social preference. P900L and WT mice both won a
246 similar number of bouts in the tube test, indicating no broad changes to social dominance or
247 hierarchies (Figure 3L; Supplemental Figure 2K). However, when we measured isolation-
248 induced vocalizations in mouse pups, we found that mutant pups call significantly less when
249 removed from the nest indicating deficits in early communication behaviors (Figure 3M). Overall
250 spectral, temporal, and body weight features were largely unchanged, with slight decreases in
251 volume, suggesting no major motor, developmental, or respiratory deficits are driving this social
252 phenotype (Supplemental Figure 2L-N). These results show that the P900L mutation causes
253 significant deficits in neonatal communication behavior.

254 Effects in somatosensory processing have been implicated as a driver of behavioral
255 phenotypes in ASD, and mice carrying mutations in ASD-associated genes have been shown to
256 have deficits in tactile discrimination (Orefice et al., 2019; Orefice et al., 2016). Therefore, we
257 next measured tactile discrimination using a textured novel object recognition (NORT) task in
258 which mice explore objects that are visually indistinguishable but differ in texture. We found that
259 WT mice showed a preference to explore a novel tactile object, and this preference was lost in
260 the P900L mutant (Figure 3N; Supplemental Figure 2O). To directly test if this lack of preference
261 was due to differences in tactile discrimination or more general novelty discrimination deficits,
262 we re-ran this task using visually and physically distinct objects and found that mutant and WT
263 littermates displayed similar preferences for novel objects (Figure 3O; Supplemental Figure 2P).
264 This indicates that P900L mutants have alterations in tactile discrimination rather than broad
265 associative memory deficits or changes in novelty-seeking behaviors. This specific deficit in
266 somatosensory processing indicates potential changes in the peripheral nervous system or
267 sensory processing and suggests such deficits may contribute to autism phenotypes in affected
268 individuals.

269 The R878H mutation generally causes more severe behavioral deficits than those
270 observed here in the P900L mutant (Smith et al., 2021); however, it remains unknown if the
271 R878H mutant demonstrates social or tactile phenotypes. Therefore, we tested the R878H
272 mutant model for changes in ultrasonic vocalizations, social hierarchies, and tactile
273 discrimination. We found that this model exhibited robust changes in social hierarchies, as
274 shown by mutants overwhelmingly winning bouts in the tube test (Figure 3P). Interestingly, this
275 change in behavior is not driven by a change in body weight, as DNMT3A mutants develop late
276 onset obesity and did not have a significant difference in body weight at the time of testing

277 (Supplemental Figure 2Q). Furthermore, in the majority of R878H wins, the mutant mouse
278 actively moved into the tube and pushed the other mouse out, indicating that the wins were not
279 due to lack of movement or activity (Supplemental Figure 2R). To further examine social
280 phenotypes, we next measured pup ultrasonic vocalizations and found that R878H mutants also
281 called significantly less than WT littermates when isolated from the nest, indicating decreases in
282 pup communication (Figure 3Q). Pups showed no major deficits in motor or respiratory
283 measures, with slight decreases in mean frequency of calls, indicating that major motor or
284 respiratory phenotypes are not driving this decrease in communication (Supplemental Figure
285 2S-U). However, the R878H mutants did weigh significantly less than WT littermates during this
286 developmental window (Supplemental Table 1), thus we cannot rule out developmental delay as
287 an underlying cause of this phenotype. Finally, we assessed tactile discrimination and found
288 that R878H mutant mice, unlike WT littermates, have no preference for a novel tactile object
289 (Figure 3R; Supplemental Figure 2V). R878H mutants also lack a preference for visually distinct
290 novel objects, indicating that this may potentially be a broader associative learning and memory
291 disruption (Figure 3S; Supplemental Figure 2W). These data demonstrate that the R878H and
292 P900L mutants share communication and tactile discrimination deficits.

293 Together, our findings indicate that the P900L mutation does not cause deficits in
294 activity, exploration, or anxiety-like behaviors, contrasting previous findings for R878H mutants
295 (Smith et al., 2021) and DNMT3A heterozygous KO mice (Christian et al., 2020), suggesting
296 that these are not central phenotypes consistently associated with DNMT3A disruption. We also
297 identify robust changes in social hierarchies in the R878H mutant, which in combination with
298 previous work, supports uniquely strong phenotypes in this mutant. These results suggest that
299 the R878H and KO mutations are more severe than the P900L, but all mutants display some
300 disease-relevant behavioral deficits such as decreases in ultrasonic vocalizations and loss of
301 preference for novel tactile objects. Additionally, shared phenotypes may be particularly
302 important measures for future work investigating cellular and molecular changes that may be
303 contributing to disease.

304

305 **Differential alterations in DNA methylation mirror differential phenotypic severity in** 306 **DNMT3A mutant mice**

307 Given the critical role DNA methylation plays in nervous system function, we
308 hypothesized that altered methylation in the brain is a central driver of disease, and that
309 differential levels of disruption between mutants may contribute to variable phenotypic severity.
310 We therefore examined how P900L and R878H mutations affect DNA methylation in the brain

311 by using whole genome bisulfite sequencing to measure DNA methylation across a variety of
312 brain regions (Figure 4A-B). Strikingly, in all brain regions the P900L mutants had a ~50%
313 reduction of genome-wide mCA, and the R878H mutants had an even more severe ~75%
314 reduction of CA methylation (Figure 4A). Effects on global mCG levels were less dramatic, with
315 trending reductions of global mCG in the P900L mutant and significant reductions in the R878H
316 mutant (Figure 4B). Thus, mutation of DNMT3A causes a widespread reduction of neuronal
317 methylation, and mCA levels are particularly sensitive to DNMT3A disruption.

318 To systematically assess altered DNA methylation and its potential impact on gene
319 regulation we next interrogated methylation changes at kilobase scale regions including
320 enhancers and gene bodies. We performed high-depth sequencing in the cerebral cortex, as
321 this is a region involved in behavioral processes disrupted in individuals with TBRS. This
322 analysis confirmed broad reductions in mCA without profound global reductions in mCG (Figure
323 4C). To uncover site-specific changes in DNA methylation, we identified CG differentially
324 methylated regions (DMRs) between sex-matched littermate pairs for both mutants. This
325 analysis revealed thousands of hypo-methylated DMRs, with only a few hundred hyper-
326 methylated DMRs in both mutants (Figure 4D-E). We detected 19,487 DMRs (196 hyper- and
327 19,291 hypo-DMRs) in the R878H mutant, while only 4,021 DMRs (215 hyper- and 3,906 hypo-
328 DMRs) were observed in the P900L mutant, further indicating more dramatic methylation
329 changes in the R878H mutant. Notably, however, hypo-DMRs called in one mutant were still
330 generally also hypo-methylated in the other, demonstrating a broad concordance of effects with
331 differing degrees of impact (Figure 4E-F). Interestingly, hyper-DMRs were not consistent
332 between mutants suggesting these effects may be stochastic or secondary to DNMT3A
333 disruption (Figure 4F). To further understand how these DMRs may be affecting transcription,
334 we assessed their location in the genome and found that DMRs tend to fall in gene regulatory
335 regions more than expected by chance, especially at CpG shores, enhancers, and regions that
336 gain methylation during postnatal neuronal maturation (Adult DMRs) (Figure 4G). Thus, both
337 mutants have numerous hypo-DMRs in critical gene regulatory regions, with R878H mutants
338 displaying more severe effects than P900L mutants.

339 While DMR calling identifies a population of significantly altered mCG sites, DNMT3A
340 mutants also display widespread changes in mCA that impact genomic regulatory regions but
341 cannot be detected by DMR calling due to limitations in statistical power. Therefore, we next
342 quantified overall levels of mCA and mCG across a number of regions of interest such as gene
343 bodies, promoters, and enhancers. We found significant reductions in mCA and mCG at gene
344 bodies and enhancers, and significant changes in mCA at promoters (Figure 4H-I). Regions that

345 gain CG methylation during postnatal neuronal development (Adult DMRs) are particularly
346 susceptible to DNMT3A disruption and have more dramatic changes (Figure 4I). The R878H
347 mutant displayed significantly more reduction of mCA than the P900L across all regions, with
348 more dramatic reductions of mCG compared to the P900L mutation at all sites examined
349 (Figure 4H-I), thus highlighting the increased severity of the R878H mutation. These results
350 indicate that both mutants exhibit loss of DNA methylation at critical genome regulatory regions
351 that have the potential to affect enhancer activity and gene expression. Furthermore, these
352 results demonstrate that the R878H mutation causes a more dramatic loss in neuronal
353 methylation than the P900L mutation, which may drive an increase in phenotype severity.

354

355 **Altered enhancer activity corresponds with DNA methylation loss in P900L and R878H** 356 **mutants**

357 Enhancers are cis-regulatory elements important for controlling gene expression, and
358 DNA methylation at both CA and CG sites control enhancer activity through effects on
359 transcription factor binding and recruitment of methyl-DNA binding factors (Clemens & Gabel,
360 2020; Giacomani-Lozano et al., 2022; Kozlenkov et al., 2014). To determine if DNMT3A mutants
361 have varied disruption of enhancers corresponding to their differential changes in DNA
362 methylation, we examined enhancer activity by ChIP-seq of Histone H3 lysine 27 acetylation
363 (H3K27ac), a histone modification correlated with active enhancers. We measured H3K27ac in
364 the cortex of 8-week P900L and R878H mutants as well as WT littermates and used EdgeR to
365 define changes at enhancers, allowing us to assess whether enhancers containing hypo- or
366 hyper-CG DMRs were dysregulated. Enhancers containing a hypo-CG DMR showed significant
367 increases in H3K27ac in the R878H mutant, and a trend towards upregulation in the P900L
368 mutant (Figure 5A). To examine the relationship between mCA and enhancer activity more
369 closely, we measured changes in mCA at the most significant 1% of upregulated and
370 downregulated enhancers, allowing for comparison of both mutants using a similarly sized
371 group of enhancers. This analysis revealed a more dramatic loss of mCA in upregulated
372 enhancers compared to unchanged enhancers in both mutants (Figure 5B). These findings
373 suggest that changes in mCA contribute to altered enhancer activity in both mutants, indicating
374 a shared mechanism that may disrupt gene expression.

375 Our analysis of enhancers with significantly altered activity suggest more dramatic
376 changes in the R878H mutant, however both mutants exhibited significant disruption of DNA-
377 methylation broadly across the genome. Therefore, we next asked if there were broad changes
378 in enhancer activity that correlate with genome-wide differences in DNA methylation and

379 assessed if these changes differentially occur in P900L and R878H mutants. This analysis
380 revealed that enhancers with a high density of WT mCA sites (mCA/kb) exhibited the largest
381 corresponding loss of mCA in both mutants, and the greatest increases in H3K27ac (Figure 5C).
382 Similarly, enhancers with low WT levels of mCA showed the smallest reductions in mCA and a
383 decrease in relative H3K27ac. While this effect was observed in P900L mutants, the R878H
384 mutation caused more dramatic changes in mCA corresponding with increased enhancer
385 disruption. Genome-wide mCG-driven changes in enhancer activity are more subtle, implying
386 that perhaps only a subset of enhancers with robust mCG differences are affected in either
387 mutant (Figure 5C). This indicates that enhancers across the genome are sensitive to changes
388 in mCA, and that DNMT3A-driven methylation changes at enhancers have the potential to
389 contribute to gene expression changes.

390 DNMT3A and MeCP2 cooperate to regulate enhancer activity (Boxer et al., 2020;
391 Clemens et al., 2019), therefore we next asked if enhancers most sensitive to MeCP2 disruption
392 are differentially affected in the R878H mutant compared to the P900L mutant. Enhancers
393 repressed by MeCP2 displayed greater loss of mCA in both mutants compared to other
394 enhancers (Figure 5D). This increased loss of methylation is accompanied by a corresponding
395 increase in H3K27ac for both mutants, with a more pronounced effect in the R878H mutant
396 compared to the P900L mutant (Figure 5E). Thus, highly methylated enhancers are regulated
397 by MeCP2, and loss of DNMT3A-dependent methylation at these enhancers causes
398 overlapping disruption with loss of MeCP2, indicating shared effects between these two
399 epigenetic regulators.

400

401 **Core disruption of growth genes across mutants with differential effects on synaptic and** 402 **protein processing genes**

403 DNA methylation and enhancer activity are critical for neurons to tune gene expression
404 programs that contribute to development and function of the nervous system, and changes in
405 gene expression can cause cellular and circuit disruption to drive disease phenotypes. We
406 therefore used RNA-seq of cerebral cortex from 8-week mutant and WT littermate pairs to
407 define alterations in transcriptional programs. P900L mutants displayed fewer significantly
408 changed genes (Figure 6A: 892 up, 581 down) compared to R878H mutants (Figure 6B: 1,396
409 up, 1,326 down), mirroring the more severe epigenomic and behavioral effects in the R878H
410 mutant. Gene expression changes in both mutants are concordant with a model of conditional
411 deletion of DNMT3A from postmitotic neurons (Clemens et al., 2019), indicating that a number
412 of these gene expression changes are related to the postnatal neuronal function of DNMT3A

413 (Supplemental Figure 3A). Next, we used PANTHER to identify the enriched gene ontology
414 (GO) terms in upregulated and downregulated genes to uncover the biological processes that
415 may be most affected in these mutants. The genes upregulated in the P900L were enriched for
416 critical neuronal functions related to synaptic transmission and axon guidance, such as cell-cell
417 adhesion, and modulation and regulation of synaptic signaling, whereas there were no
418 significantly enriched terms associated with the P900L-downregulated genes (Figure 6C). In
419 contrast, the genes upregulated in the R878H were associated with protein folding, and the
420 downregulated genes were associated with synaptic signaling, phospholipid translocation, and
421 cell-cell recognition and assembly (Figure 6C). The distinct processes disrupted in these
422 mutants may help explain the variable presentation of phenotypes; the P900L has more subtle
423 changes in specific behavioral tasks perhaps driven by changes in synaptic and axonal genes,
424 whereas the R878H mutant shows more widespread behavioral disruption corresponding with
425 dramatic transcriptional changes involving fundamental biological processes such as protein
426 folding and phospholipid translocation.

427 To more directly assess the transcriptomic differences that could lead to distinct
428 phenotypes between mutants, we defined mutant-specific genes by identifying genes
429 upregulated in one mutant and either unchanged or downregulated in the other mutant (Figure
430 6D), and again used PANTHER to identify enriched gene ontology terms. We focused first on
431 upregulated gene lists, as these may be the most direct targets from loss of DNA methylation.
432 The P900L-specific upregulated genes again were primarily enriched for synaptic and axonal
433 projection processes, whereas the R878H-specific upregulated genes were enriched for protein
434 folding and transport terms (Figure 6E). The R878H-specific downregulated terms were
435 primarily related to glutamatergic synaptic transmission and cell-cell adhesion and organization,
436 whereas P900L-specific downregulated genes were not associated with any GO terms
437 (Supplemental Figure 3B-C). This further suggests that transcriptional disruption in the P900L
438 affects fine-tuned and sensitive neuronal processes, whereas dysregulated genes in the R878H
439 are potential indicators of more dramatic and widespread cellular distress.

440 While leveraging the transcriptional and phenotypic differences between mutants offers
441 insight into which gene sets contribute to distinct phenotypes, identifying the shared effects
442 across multiple DNMT3A mutant models can identify central biology driving common disease
443 phenotypes. Therefore, we leveraged an existing disease-relevant cortical dataset from the
444 DNMT3A deletion mouse model and analyzed it together with our new transcriptomic data to
445 identify the shared disruption in DNMT3A mutant models. We used our data from the P900L/+
446 (n=7/genotype; 4 male, 3 female) and R878H/+ (n=7/genotype; 4 male, 3 female) mutations,

447 and gene expression data from a heterozygous KO mouse (n=7/genotype; 4 male, 3 female)
448 (Christian et al., 2020), to create an aggregate dataset of heterozygous germline DNMT3A
449 models. We then used DESeq2 to compare WT and mutant gene expression between sex-
450 matched littermate pairs (design = ~ pair + group; contrast by group to identify WT vs. mutant
451 effects) thus identifying high-confidence TBRS-associated differentially expressed genes
452 (Figure 7A). This analysis identified 228 upregulated and 160 downregulated genes that show
453 concordant up- and down-regulation across mutant strains (Figure 7B). TBRS-upregulated
454 genes are enriched for processes such as cellular and developmental growth, axon extension,
455 and neural crest cell migration and no terms were significantly enriched in the downregulated
456 genes (Figure 7C). The dysregulated genes in these pathways may be critical in driving the
457 overgrowth and behavioral phenotypes identified in individuals with DNMT3A disorders and
458 represent strong candidates for future cellular and therapeutic studies.

459

460 **Genes disrupted in TBRS models are shared across disorders that impact the neuronal** 461 **methylome**

462 Multiple neurodevelopmental diseases are caused by mutations in genes associated
463 with the neuronal methylome (e.g., DNMT3A (Tatton-Brown et al., 2018), MeCP2 (Tillotson et
464 al., 2021), NSD1 (Hamagami et al., 2023)), so we next asked if transcriptomic disruption is
465 shared between multiple models of neurodevelopmental disorders. Previous work has shown
466 that deletion of MeCP2 and DNMT3A have overlapping gene expression patterns (Christian et
467 al., 2020; Clemens et al., 2019; Lavery et al., 2020), and we have established that MeCP2-
468 regulated enhancers are similarly disrupted in the P900L and R878H mutants, therefore we next
469 asked if the core TBRS-dysregulated genes overlap with the gene expression changes
470 observed in the MeCP2 KO. We performed a Rank-Rank Hypergeometric Overlap (RRHO)
471 analysis (Cahill et al., 2018) to measure transcriptome-wide correspondence between the
472 TBRS-mutant models and the MeCP2 KO and found significant overlaps in the concordant
473 quadrants (Figure 7D). Additionally, genes significantly dysregulated in MeCP2 mutants are
474 correspondingly disrupted in the TBRS mutants (Figure 7E, Supplemental Figure 3D).
475 Transcriptional overlap between this consensus TBRS dataset and the MeCP2 KO further
476 supports a shared molecular etiology between mutation of DNMT3A, which methylates the
477 neuronal genome, and MeCP2, which binds that methylation to repress transcription of genes.

478 Overlapping clinical phenotypes or shared biological pathways can be used to suggest
479 other important candidate regulators of DNMT3A and the neuronal methylome. One such
480 candidate is NSD1, a histone methyltransferase associated with Sotos Syndrome (Saugier-

481 Veber et al., 2007; Tatton-Brown et al., 2005). A significant number of patients with overgrowth
482 and intellectual disability phenotypically similar to TBRS patients have mutations in NSD1
483 (Tatton-Brown et al., 2017), and emerging studies have also demonstrated that NSD1 deposits
484 H3K36me2 to direct DNMT3A to establish methylation at key genomic regions in neurons
485 (Hamagami et al., 2023). This led us to ask if there are shared effects between NSD1 mutants
486 and the core gene dysregulation we identified in TBRS models. RRHO comparison of cortical
487 genes dysregulated in an NSD1 conditional KO model and aggregate TBRS effects indicates a
488 highly significant transcriptome-wide concordance (Figure 7F), and genes identified as
489 significantly dysregulated in the NSD1 mutant are similarly dysregulated in the TBRS mutants
490 (Figure 7G, Supplemental Figure 3E). Interestingly, for both MeCP2 and NSD1 comparisons,
491 overlaps were more pronounced in shared upregulated genes, suggesting these are the direct
492 effects of the pathway. Downregulated genes across models were more unique, suggesting
493 they may be more stochastic and less central to the shared phenotypes of the three syndromes.
494 Together these results indicate that the core sets of genes driving DNMT3A-disorders are
495 shared with models of Rett Syndrome and Sotos Syndrome. This reflects a biological
496 convergence across multiple disorders, indicating the neuronal mCA-pathway regulating gene
497 expression may be a useful target in future studies of potential therapeutics for all three
498 disorders.

499 **Discussion:**

501 Neurodevelopmental disorders (NDDs) often present with varied phenotypes and
502 numerous comorbidities, and the molecular mechanisms driving this spectrum of phenotypic
503 heterogeneity have not been clearly identified. Additionally, a substantial number of mutations
504 identified in some NDD-associated genes are missense rather than stop-gains (e.g., *KIF1A*,
505 *MEFC2*, *CHD3*, *PTEN*, *GRIN2B*, *DNMT3A*), and the effects of these diverse mutations are not
506 fully understood (Wang et al., 2020). Here, we studied missense mutations in DNMT3A to
507 investigate the origins of clinically diverse phenotypes within one causative locus, ranging from
508 ASD to severe intellectual disability. We identified behaviors that indicate varied severity of
509 alleles and linked these changes to differential disruption of neuronal methylation and
510 transcription. Through this work, we not only identified the core set of phenotypes and shared
511 genes that are central to DNMT3A-disorders, but also defined allele-specific gene networks and
512 cellular processes that may underlie the spectrum of phenotypes. Furthermore, we detected
513 transcriptional overlap between core DNMT3A gene expression effects and disruption of
514 MeCP2 and NSD1, highlighting a potential point of convergence in disease etiology and

515 therapeutic intervention. In this study, we generated a clinically-relevant germline mutation that
516 represents the larger class of “typical” missense mutations in the methyltransferase domain of
517 DNMT3A. Through our analysis, we identified skeletal development and obesity phenotypes
518 that are consistent across multiple DNMT3A mutations. The increase in long-bone length
519 shared between the P900L mutation and other mutants underscores the importance of
520 DNMT3A in skeletal development and growth. P900L mutants also exhibit similar increases in
521 body fat compared to other DNMT3A mutants (Christian et al., 2020; Smith et al., 2021; Tovy,
522 Reyes, et al., 2022), and we expand these observations by demonstrating that progressive
523 increase in fat mass can occur without changes in feeding behavior or substantial decreases in
524 exploratory behaviors. This suggests other metabolic or cellular processes may be responsible
525 for obesity in DNMT3A mutants, and further highlights the potential mechanism proposed by
526 Tovy et al. that DNMT3A mutations may cause expansion of adipocyte progenitors (Tovy,
527 Reyes, et al., 2022). These findings reinforce the importance of DNMT3A in skeletal
528 development and provide important context supporting the role of DNMT3A in obesity.

529 Our analysis of skull size and shape demonstrates that the P900L mutation does not
530 exhibit changes in skull morphology, which is similar to other mouse models of TBR1 (Christian
531 et al., 2020; Smith et al., 2021) but does not phenocopy the human disorder. We also identified
532 reductions in brain volume shared across multiple mutants. The lack of brain overgrowth in mice
533 could contribute to the lack of differences in skull size and shape, as skull development is
534 sensitive to changes in brain volume (Bartholomeusz et al., 2002). Evolutionary differences in
535 growth regulation between humans and mice may underlie these phenotypic distinctions,
536 suggesting that other approaches, such as using human cellular models, may be necessary to
537 identify the mechanisms leading to human brain overgrowth. Notably, the reduction in brain size
538 is shared between multiple mouse mutations, suggesting that the cellular processes leading to
539 decreased brain volume (e.g., changes in cell counts, cell size or dendritic arborization) are
540 highly sensitive to DNMT3A disruption. Furthermore, this may represent phenotypic overlap
541 between DNMT3A- and MeCP2-mutants that reflects the similar transcriptional disruption that
542 we observe between these models. This is further supported by the lack of brain volume
543 differences at P10, a timepoint prior to widespread MeCP2 expression in the brain.

544 Humans with DNMT3A mutations range in clinical diagnoses from ASD to severe
545 intellectual disability, and our characterization of the P900L model allowed us to identify
546 behavioral domains with similar phenotypic heterogeneity. Previous work demonstrated that
547 heterozygous loss of DNMT3A in mice causes reduced exploration and increased anxiety-like
548 behaviors (Christian et al., 2020), and R878H mutant mice have more dramatic reductions to

549 exploratory behavior and disruption of motor coordination (Smith et al., 2021). In contrast, the
550 P900L mutant has no motor, exploratory, or anxiety-like changes, indicating that these
551 phenotypes are not ubiquitous across all mouse models of DNMT3A disruption, and instead
552 may be representative of the phenotypic heterogeneity of DNMT3A disorders. We also identified
553 severe alteration of social hierarchies in the R878H mutant that are not observed in the P900L
554 mutant. These findings clearly demonstrate differences in phenotype severity and define
555 differential phenotypes that we can compare to altered epigenomic and transcriptional effects in
556 these models.

557 We expanded DNMT3A-phenotypes in mice by assessing behaviors associated with
558 ASD and identified disruption of communication and tactile discrimination shared across multiple
559 models. Altered tactile discrimination is an emerging phenotype across multiple ASD models
560 (Orefice et al., 2019; Orefice et al., 2016), indicating a potential mechanism contributing to
561 behavioral disruption, and highlighting the importance of DNMT3A in sensory processing. Our
562 study also confirms that neonatal ultrasonic vocalizations are reproducibly sensitive to DNMT3A
563 disruption, as demonstrated by the reduction in number of calls in the P900L mutants, R878H
564 mutants, and in a heterozygous KO model (Christian et al., 2020). This work establishes that
565 communication and tactile discrimination deficits are consistent and robust across DNMT3A
566 models, suggesting that these measures are a promising focus for future work testing
567 therapeutics or identifying cellular mechanisms contributing to disruption.

568 Behavioral differences in individuals with DNMT3A mutations and the numerous
569 functions of DNMT3A in nervous system development indicate importance of this protein in the
570 brain. Our work here defines how disease-associated missense mutations affect the neuronal
571 epigenome *in vivo*, thus beginning to uncover mechanisms driving behavioral phenotypes and
572 nervous system disruption. We found that the P900L mutation causes a 50% reduction of mCA
573 which mimics a heterozygous KO, supporting the hypothesis that mCA levels are a sensitive
574 readout of DNMT3A function. In contrast, the R878H mutation causes greater than 50% loss of
575 mCA, demonstrating that it drives more dramatic effects than other mutations. While our results
576 do not shed light on the exact mechanism leading to this effect, this *in vivo* result supports
577 studies in the blood lineage indicating that R878H mutation is dominant-negative (Russler-
578 Germain et al., 2014). In addition to these insights, our study illustrates the sensitivity of global
579 mCA levels to different DNMT3A mutations and suggests that even weak loss of function
580 mutants may have alterations in global mCA levels. Differences in allele-severity are further
581 reflected by the increase in number of DMRs in the R878H mutant compared to the P900L
582 mutant, and we demonstrate that these methylation differences overlap with key genomic

583 regulatory elements such as gene bodies and enhancers. Notably, we found increased
584 enhancer disruption in the R878H mutant that corresponds to larger changes in mCA at
585 enhancers. This enhancer effect is similar to observations in MeCP2 mutants, and we
586 demonstrate that DNMT3A mutants have concordant disruption of enhancers regulated by
587 MeCP2. Together, these results are the first to demonstrate how disease-associated missense
588 mutations in DNMT3A differentially disrupt numerous neuronal epigenomic processes and
589 suggest a molecular mechanism driving the spectrum of phenotypic severity.

590 Our work defined mutation-specific gene expression changes to gain insights into the
591 cellular disruptions and biological pathways that may be driving the spectrum of disease
592 phenotypes. The P900L mutation causes disruption of fine-tuned neuronal genes related to
593 synaptic function and axonal guidance, suggesting that synapses, axon projections, and circuit
594 connectivity may be disrupted in mutants. It is possible that these transcriptional changes are
595 contributing to the reduction in FA measured in the P900L corpus callosum, indicating potential
596 disruption of long-range axonal projections in this model. The R878H mutation caused more
597 extensive transcriptomic disruption, altering gene networks involved in key cellular processes
598 such as protein folding and molecular transport. These allele-specific transcriptomic effects
599 identify cellular mechanisms that may underlie the unique behavioral phenotypes and provide
600 compelling candidates for future work on distinct cellular- and circuit-level effects in DNMT3A
601 disorders.

602 Our characterization of transcriptional disruption in multiple models allowed us to define
603 the core sets of neuronal genes most sensitive to DNMT3A mutation that may contribute to
604 TBRS pathology. Genes consistently dysregulated across DNMT3A mutants suggest cellular
605 mechanisms that may be disrupted in TBRS. Upregulation of NDD-associated genes such as
606 the Semaphorin family (*Sema3b*, *Sema3e*, *Sema4a*, and *Sema5a*) and *Tbr1* suggest changes
607 in axon guidance and migration may contribute to TBRS pathology, and these effects could be
608 involved in disruption of ultrasonic vocalizations in mice (Co et al., 2022; Duan et al., 2014;
609 Fazel Darbandi et al., 2018, 2020; T. N. Huang et al., 2014; Sollis et al., 2022; Zhao et al.,
610 2018). Changes in sensory neurons contributing to NORT phenotypes in DNMT3A mutants may
611 be related to disruption of *Etv4*, *Myocilin*, and *Begain*, as these genes are important for the
612 proper development, growth, and myelination of peripheral neurons (Katano et al., 2016; Kwon
613 et al., 2013; Ríos et al., 2022; Smit et al., 2005; Yao et al., 1996). Finally, downregulation of
614 *Sox21* and *Gabrg1* in DNMT3A mutants suggest potential changes in GABAergic interneurons
615 and precursors (Makrides et al., 2018; Polan et al., 2014) which may be playing a role in
616 developmental delay (Williams et al., 2022). Importantly, several classes of interneurons have

617 high global levels of mCA (Mo et al., 2015), offering a potential mechanism to explain why
618 interneurons may be uniquely vulnerable to loss of DNMT3A function. Together, this work
619 defines the gene sets and processes that are most susceptible to DNMT3A disruption and
620 provides insights into potential biological processes and cell types that could contribute to
621 disease.

622 Finally, our study has detected transcriptional convergence between core gene
623 dysregulation in TBRS models and mutations in other proteins in the neuronal-methylome
624 pathway, supporting potential functional links between Sotos syndrome, TBRS, and Rett
625 Syndrome. The transcriptional similarities between disruption of DNMT3A and other epigenetic
626 regulators highlights the importance of this pathway for neuronal gene regulation and indicates
627 a therapeutic point of convergence across an entire class of NDDs.

628

629 **Figure Legends:**

630 **Figure 1: P900L mutants have increases in bone length and progressive obesity**

- 631 (A) Representative dual x-ray image of femurs isolated from 30-week WT and P900L
632 littermates.
- 633 (B) Quantification of femur length (P900L n=18, 10 male, 8 female; WT n=16, 9 male, 7 female;
634 2-way ANOVA, genotype ** $p < 0.01$).
- 635 (C) Principal components analysis of skull landmark distances (P900L n=8, 4 male, 4 female;
636 WT n=8, 4 male, 4 female).
- 637 (D) Example image of reconstructed skull from μ CT imaging with significant linear distances
638 shown. Blue lines indicate distances that were significantly longer in the WT compared to
639 the P900L, and no distances were significantly longer in the P900L.
- 640 (E-G) Quantification of body weight (E) and EchoMRI measures of lean mass (F) and fat mass
641 (G) (P900L n=15, 8 male, 7 female; WT n=17, 10 male, 7 female; 2-way ANOVA, genotype
642 ** $p < 0.01$).
- 643 (H) Body weights of animals on a high-fat diet measured weekly for 20 weeks (P900L n=18, 10
644 male, 8 female; WT n=16, 9 male, 7 female; 3-way repeated measures ANOVA; genotype
645 $p = 0.022$; genotype by time $p < 0.0001$)
- 646 (I) Daily food intake between 30-week WT and P900L animals that had been on a high fat diet
647 for 20 weeks is not significantly changed (P900L n=9, 3 male, 6 female; WT n=14, 7 male, 7
648 female; Unpaired T-Test $p = 0.624$).

649 Results are expressed as mean \pm SEM. No significant sex-genotype interactions observed.

650

651 **Figure 2: DNMT3A mutations cause reductions in brain volume and cortical thickness**

- 652 (A) Representative MRI image (left) and whole brain segmentation (right). D-Dorsal, V-Ventral,
653 A-Anterior, P-Posterior.
- 654 (B) Quantification of whole brain volume from WT and P900L adults.
- 655 (C) Representative MRI image of fractional anisotropy (FA) of corpus callosum (left) and
656 example segmentation (right).
- 657 (D-E) Quantification of corpus callosum volume (D) and FA (E) in WT and P900L animals.

658 (F) Representative image of cortical thickness measurements.
659 (G) Quantification of cortical thickness across various regions (3-way repeated measures
660 ANOVA, genotype $p < 0.0001$, region $p < 0.0001$).
661 (H) Representative image of ventricles from an ADC image (left), and example segmentation
662 (right).
663 (I) Quantification of ventricular volume in WT and P900L animals.
664 (J-N) Quantification of WT and R878H whole brain volume (J), corpus callosum volume (K) and
665 FA (L), ventricular volume (M) and cortical thickness (N) (Cortical thickness: 3-way
666 repeated-measures ANOVA, genotype $p < 0.05$, region $p < 0.0001$).
667 (O-P) Brain volume measurements at P10 shows no significant difference between P900L
668 mutants (O) or R878H mutants (P) and their WT littermates.
669 Results are expressed as mean \pm SEM with individual animals shown. Genotype effect from 2-
670 way ANOVA and significant within-sex comparisons with Sidak's multiple testing correction are
671 shown. As some measures showed a significant sex-effect, sexes were separated, and sex is
672 included as a factor. Detailed statistics, and sample sizes in Supplemental Table 1. * $p < 0.05$; **
673 $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$

674
675 **Figure 3: P900L mutants do not show activity or anxiety-like phenotypes, but do have**
676 **changes in social and tactile behaviors**

677 (A) Measurement of movement in an open field assay over 60 minutes.
678 (B) Marble burying behavior over a 30-minute period.
679 (C) Time in the center of an open field assay.
680 (D) Time in the open arms of an elevated plus maze.
681 (E-F) Time spent freezing in a conditioned fear assay. Animals were trained to associate an
682 environment and a stimulus (tone) with a small foot-shock, and freezing behavior was
683 recorded. P900L mutants had similar time spent freezing compared to WT littermates for
684 both the environmental context alone (E), and in response to the tone (cue) stimuli (F).
685 (G-J) Measures of spatial learning and memory in a Morris Water Maze. During cued trials (G)
686 the escape platform was visible, and path length to escape platform was measured. P900L
687 animals had significantly longer path length when initially exposed to the task, but no
688 differences by trial 4. During place trials (H) the platform was no longer visible, and
689 genotypes had similar path lengths to reach the escape platform. (I) Time in quadrants after
690 the platform was removed indicates no significant differences in target zone, and (J) both
691 genotypes crossed over where the escape platform had been located a similar number of
692 times.
693 (K) In a 3-chamber social approach assay, P900L and WT animals both had a similar
694 preference index for a mouse rather than an object, and for a novel mouse rather than a
695 familiar one. Both genotypes showed a significant non-zero preference for interacting with
696 conspecific mouse over an object, and for interacting with a novel conspecific over a familiar
697 conspecific. All preference indexes range from -1 to 1.
698 (L) Tube test percentage of bouts won, indicating that WT and P900L animals were equally
699 likely to win bouts. (n=140 bouts)
700 (M) Ultrasonic vocalizations of P900L and WT P5-P9 pups when isolated from the nest.

- 701 (N) Preference index for the novel object during a tactile novel object recognition assay for WT
702 and P900L animals. One-sample T-Test to determine if preference index is significantly
703 different than 0 is indicated for both genotypes.
- 704 (O) Preference index for a visually distinct novel object for P900L and WT animals. One sample
705 T-Test to determine if preference index is significantly different than 0 is indicated.
- 706 (P) Tube test percentage of bouts won, indicating that R878H animals won significantly more
707 bouts than WT animals. (n=51 bouts)
- 708 (Q) Ultrasonic vocalizations of WT and R878H pups when isolated from the nest.
- 709 (R) Preference index for the novel object during a tactile novel object recognition task for WT
710 and R878H animals. One-sample T-Test to determine if preference index is significantly
711 different than 0 is indicated for both genotypes.
- 712 (S) Preference index for visually distinct novel object for R878H and WT animals. One sample
713 T-Test to determine if preference index is significantly different than 0 is indicated.
- 714 Graphs indicate mean \pm SEM. Detailed statistics, and sample sizes in Supplemental Table 1. *
715 $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$

716

717 **Figure 4: DNMT3A mutants have significant changes to DNA methylation, with more**
718 **extreme changes in the R878H mutant compared to the P900L**

- 719 (A-B) Average genome-wide methylation levels from brain regions measured using whole
720 genome bisulfite sequencing for (A) percent mCA and (B) percent mCG for both P900L and
721 R878H mutants and their WT littermates. (All groups n=4, 2 male, 2 female; Unpaired
722 Student's T-Test with Bonferroni Correction)
- 723 (C-D) Representative genome browser view showing percent mCA and mCG (C). (D) Zoomed
724 in browser to show changes in CG at hypo-differentially methylated regions (DMRs).
- 725 (E) Heatmap of CG-DMRs identified in P900L and R878H mutants vs. their WT littermates.
726 $\log_2(\text{Fold change mCG/CG})$ indicated between each littermate pair for each DMR.
- 727 (F) Average mCG in each genotype at DMRs called in both mutant strains. Both mutants show
728 a consistent decrease at hypo-DMRs called in either mutant. Hyper-DMRs are only
729 significant in the strain they were defined in.
- 730 (G) Overlap analysis of DMRs with genomic regions of interest. Adult DMRs are the regions that
731 significantly gain mCG over postnatal development in neurons (Lister et al. 2013). No point
732 indicated for R878H Hyper-DMRs CpG islands, due to 0 resampled DMRs overlapping.
733 Significance assessed with a Chi-Squared test with expected proportions of overlapping and
734 nonoverlapping measured by resampling DMRs.
- 735 (H) Average mCA level at regions of interest (top) and percent reduction of mCA between WT
736 and mutants (bottom).
- 737 (I) Average mCG level at regions of interest (top) and percent reduction of mCG between WT
738 and mutants (bottom). Promoters and CpG islands have low levels of mCG, and a trending,
739 but not significant difference between P900L and R878H loss.
- 740 Bar graphs indicate mean \pm SEM. Notched box and whisker plots indicate median, interquartile,
741 and confidence interval of median. All groups n=4, 2 male, 2 female. Detailed statistics, and
742 sample sizes in Supplemental Table 1. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; # $p < 0.0001$; ## $p < 2 \times 10^{-10}$

743

744 **Figure 5: Methylation changes in DNMT3A mutants disrupt enhancer activity**

- 745 (A) \log_2 fold changes of H3K27ac at enhancers containing DMRs called in that mutant.

- 746 (B) Change in mCA/kb (mutant – WT) for the top and bottom 1% of enhancers. The most
747 significantly upregulated and downregulated enhancers were called between WT and
748 mutants, and the average methylation loss at those enhancers was measured.
749 (C) Genome-wide deciles of WT mCA or mCG sites per kilobase at enhancers, and the loss of
750 methylation and fold change in H3K27ac at these sites in both P900L and R878H mutants.
751 (D) Mean mCA sites per kilobase in DNMT3A mutants and their WT littermates (top), and the
752 change in mCA sites per kilobase between mutants and WT littermates (bottom) at
753 enhancers significantly dysregulated in MeCP2 mutants (Clemens *et al.*, 2019).
754 (E) Log₂ fold changes in H3K27ac between mutants and WT littermates at enhancers
755 significantly dysregulated in MeCP2 mutants (Clemens *et al.*, 2019).
756 Bar graphs indicate mean ± SEM. Notched box and whisker plots indicate median, interquartile,
757 and confidence interval of median. All groups n=4, 2 male, 2 female. Detailed statistics, and
758 sample sizes in Supplemental Table 1. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; # $p < 0.0001$; ## $p < 2 \times 10^{-10}$
759

760 **Figure 6: Mutation-specific changes in transcription indicate unique disruption in**
761 **synaptic and protein processing gene networks**

- 762 (A) Volcano plot of DESeq2 log₂ fold changes in P900L vs. WT cortex. Genes reaching a
763 significance of $p_{adj} < 0.1$ are indicated in purple and pink.
764 (B) Volcano plot of DESeq2 log₂ fold changes in R878H vs. WT cortex. Genes reaching a
765 significance of $p_{adj} < 0.1$ are indicated in blue and orange.
766 (C) Most significant PANTHER gene ontology (biological process) terms enriched in each
767 differentially expressed gene list. No significant terms were identified in the P900L-
768 downregulated gene list.
769 (D) P900L- and R878H-specific upregulated gene sets indicated in purple and teal. Specific
770 genes are defined as those that are significantly upregulated in one mutant, and either
771 significantly unchanged (nominal p-value > 0.5) or downregulated in the other (fold
772 change < 0).
773 (E) Most significant PANTHER gene ontology (biological process) terms enriched in P900L-
774 specific and R878H-specific upregulated gene lists.
775

776 **Figure 7: Shared transcriptional changes across DNMT3A mutants indicate disruption of**
777 **growth and synaptic processes**

- 778 (A) Volcano plot of DESeq2 log₂ fold changes from DNMT3A mutant vs. WT littermate
779 analysis between littermate paired data from DNMT3A^{KO/+} (Christian *et al.*, 2020),
780 DNMT3A^{R878H/+}, and DNMT3A^{P900L/+} datasets (design = ~ pair + group; contrast by
781 group). Genes reaching a significance of $p_{adj} < 0.1$ are indicated in blue and pink.
782 (B) Log₂ fold changes of gene expression within each mutant (KO/+, P900L, and R878H) of
783 genes defined as differentially expressed in the combined TBRS-mutant analysis.
784 (C) Most significant PANTHER gene ontology (biological process) terms enriched in the
785 TBRS differentially expressed gene lists. No significant terms were identified in the
786 TBRS-downregulated gene list.
787 (D) Rank-rank hypergeometric overlap (RRHO) of transcriptome-wide gene expression
788 changes in the cerebral cortex of TBRS mutants versus MeCP2 KO mice (Clemens *et al.*, 2019).
789 (E) Log₂ fold changes in the TBRS mutants at genes significantly disrupted in MeCP2
790 mutants (Clemens *et al.*, 2019).
791 (F) RRHO of transcriptome-wide gene expression changes in the cerebral cortex of TBRS
792 mutants versus NSD1 conditional KO mice (Hamagami *et al.*, 2023).
793 (G) Log₂ fold changes in the TBRS mutants at genes significantly disrupted in NSD1 cKO
794 cortices (Hamagami *et al.*, 2023).
795

796 Notched box and whisker plots indicate median, interquartile, and confidence interval of median
797 with significance from Wilcoxon Rank Sum test shown. Detailed statistics, and sample sizes in
798 Supplemental Table 1. # $p < 0.0001$; ## $p < 2 \times 10^{-10}$
799

800 **Supplemental Figure 1: Generation of the P900L mutant model**

- 801 (A) Sanger sequencing tracks indicating heterozygous P900L point mutation. The WT CCG
802 codon is changed to a P900L CTG codon, with the mutation highlighted in blue.
803 (B) Example gel from restriction enzyme genotyping from WT and P900L/+ ear lysate. Digested
804 WT PCR products are at approximately 285bp and 421bp, whereas P900L PCR products
805 are undigested and remain at the full 706bp.
806 (C) Representative image of WT and P900L mouse at 30 weeks of age.
807 (D) Quantification of DNMT3A expression from 2-week cortex by RT-qPCR (n=5/genotype, 3
808 males, 2 females) and western blot (n=8/genotype, 4 males, 4 females). Student's T-Test; *
809 $p < 0.05$.

810 Box plot indicates 25th percentile, median, and 75th percentile. Whiskers indicate minimum and
811 maximum.

812

813 **Supplemental Figure 2: P900L mutants do not show activity or anxiety-like phenotypes, 814 but do have changes in social and tactile behaviors**

- 815 (A-B) Time on a continuous (A) or accelerating (B) rotarod indicates no significant differences
816 between WT and P900L animals.
817 (C) Walking initiation assay, with time to leave a marked square measured.
818 (D-F) Genotypes had no significant differences in latency to fall of a (D) ledge, (E) platform, or
819 (F) an inverted screen.
820 (G-H) Genotypes had no significant differences in time taken to (G) turn and climb down a pole,
821 or (H) time to the top of a 60° or 90° screen.
822 (I) Time freezing during conditioned fear training, during baseline (before tone and shock) and
823 during tone and shock association training.
824 (J) Distance traveled during the 3-chamber social approach assay.
825 (K) Body weights of animals during tube test assay indicate no significant differences between
826 genotypes for the P900L animals vs. WT littermates. Body weight and size can have a
827 significant impact on social hierarchies, and testing was done before mutants increased in
828 size.
829 (L-N) Measures of volume (L), average frequency (M), and duration (N) of ultrasonic
830 vocalization calls in the WT and P900L animals.
831 (O-P) Time spent investigating objects in NORT (O) and NOR (P) trials for WT and P900L
832 animals.
833 (Q) Body weight of R878H animals vs. WT littermates during tube test trials.
834 (R) Active vs. Passive animal status during R878H or WT wins (see methods).
835 (S-U) Measures of volume (S), average frequency (T), and duration (U) of ultrasonic
836 vocalization calls in the WT and R878H animals.
837 (V-W) Time spent investigating objects in NORT (V) and NOR (W) trials for WT and R878H
838 animals.

839 Bar graphs and line plots indicate mean \pm SEM; Box-and-whisker plots indicate mean and
840 quartiles. Detailed statistics, and sample sizes in Supplemental Table 1.

841

842 **Supplemental Figure 3: P900L and R878H mutants exhibit transcriptional overlap with**
 843 **other models disrupting the neuronal epigenome, and mutants also exhibit specific**
 844 **downregulated effects**

- 845 (A) Log₂ fold changes in the P900L- and R878H- mutants at genes significantly disrupted
 846 upon homozygous KO of DNMT3A in postmitotic neurons (Clemens *et al.*, 2019)
 847 (B) P900L- and R878H-specific downregulated gene sets indicated in purple and teal.
 848 Specific genes are defined as those that are significantly downregulated in one mutant,
 849 and either significantly unchanged (nominal p-value > 0.5) or upregulated in the other
 850 (fold change > 0).
 851 (C) Most significant PANTHER gene ontology (biological process) terms enriched in P900L-
 852 specific and R878H-specific downregulated gene lists. No terms were significantly
 853 enriched in the P900L-specific downregulated gene sets.
 854 (D) Log₂ fold changes in the P900L- and R878H- mutants at genes significantly disrupted in
 855 MeCP2 mutants (Clemens *et al.*, 2019)
 856 (E) Log₂ fold changes in the P900L- and R878H- mutants at genes significantly disrupted in
 857 upon homozygous KO of NSD1 in neural progenitors (Hamagami *et al.*, 2023)

858 Notched box and whisker plots indicate median, interquartile, and confidence interval of median
 859 with significance from Wilcoxon Rank Sum test shown. Detailed statistics, and sample sizes in
 860 Supplemental Table 1. ** $p < 0.01$; *** $p < 0.001$; # $p < 0.0001$; ## $p < 2 \times 10^{-10}$

861

862 **STAR METHODS**

863

864 **Key Resources Table**

865

REAGENT or RESOURCE	SOURCE	IDENTIFIR
Antibodies		
Rabbit monoclonal anti-alpha-Tubulin (EP1332Y)	Abcam	Cat# ab52866 RRID: AB_869989
Mouse Anti-Dnmt3a Monoclonal Antibody, Clone 64B1446	Abcam	Cat# ab13888 RRID: AB_300714
IRDye 800CW Goat anti-Rabbit IgG antibody	LI-COR Biosciences	Cat# 926-32211 RRID: AB_621843
IRDye 800CW Goat anti-Mouse IgG antibody	LI-COR Biosciences	Cat# 926-32210 RRID: AB_621842
Rabbit polyclonal anti-Histone H3 (acetyl K27)	Abcam	Cat# ab4729 RRID: AB_2118291
Bacterial and Virus Strains		
Chemicals, Peptides, and Recombinant Proteins		
Critical Commercial Assays		
Mspa11	NEB	Cat# R0577
AllPrep DNA/RNA Kit	QIAGEN	Cat# 80284
Ovation Ultralow Methyl-Seq Kit	Tecan	Cat# 0335-32
Epiect Bisulfite Kit	Qiagen	Cat# 59824

EZ DNA Methylation-Direct Kit	Zymo Research Corporation	Cat# D5020
Accel-NGS Methyl-Seq DNA Library Kit	Swift Biosciences	Cat# 30024
NEBNext Ultra Directional RNA Library Prep Kit for Illumina	NEB	Cat# E7420
NEBNext rRNA Depletion Kit (Human/Mouse/Rat)	NEB	Cat# E6310
Accel-NGS 2S Plus DNA Library Kit (24 rxns)	Swift Biosciences	Ca# 21024
Oligonucleotides		
<i>Actb</i> Forward	IDT	AAGGCCAACCGTGAAAAGAT
<i>Actb</i> Reverse	IDT	GTGGTACGACCAGAGGCATAC
<i>Dnmt3a</i> Forward	IDT	GGCCTTCTCGACTCCAGATG
<i>Dnmt3a</i> Reverse	IDT	TTCCTCTTCTCAGCTGGCAC
<i>Dnmt3a P900L</i> Region Forward	IDT	AGAGGGGCATTTATGGATGA
<i>Dnmt3a P900L</i> Region Reverse	IDT	GAGGGGCCTATTTTGCTTTT
Recombinant DNA		
Deposited data		
RNA-sequencing data	This paper	GEO: GSE225372
ChIP-sequencing data (H3K27ac)	This paper	GEO: GSE225372
Bisulfite-sequencing data	This paper	GEO: GSE225372
Bisulfite-sequencing data	(Lister et al., 2013)	GEO: GSE47966
RNA-, ChIP-, and Bisulfite-sequencing data	(Clemens et al., 2019)	GEO: GSE123373
RNA-sequencing data	(Christian et al., 2020)	GEO: GSE147899
RNA-sequencing data	(Hamagami et al., 2023)	GEO: GSE212847
Mus musculus mm9 genome assembly	UCSC	http://hgdownload.soe.ucsc.edu/goldenPath/mm9/
Ensembl gene models	UCSC	https://genome.ucsc.edu/cgi-bin/hgTables
Experimental models: organisms/strains		
C57BL/6J	The Jackson Laboratory	JAX:000664
<i>Dnmt3a</i> P900L/+	This paper	
<i>Dnmt3a</i> R878H/+	(Smith et al. 2021)	Provided by T. Ley
Experimental models: cell lines		
Software and Algorithms		

DESeq2 (v1.14.1)	(Love et al., 2014)	http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html
edgeR (v3.16.5)	(Robinson et al., 2009)	https://bioconductor.org/packages/release/bioc/html/edgeR.html
SAMtools (v1.3)	(Li and Durbin, 2009)	https://sourceforge.net/projects/samtools/files/
BEDtools2 (v2.25.0)	(Quinlan and Hall, 2010)	https://github.com/arq5x/bedtools2
Bowtie2 (v2.2.5)	(Langmead and Salzberg, 2012)	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
STAR	(Dobin et al., 2013)	https://github.com/alexdobin/STAR
fastQC		https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
Trim galore		https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/
BS-seeker2	(Guo et al., 2013)	https://github.com/BSSeeker/BSSeeker2
BSmooth	(Hansen et al., 2012)	https://www.bioconductor.org/packages/release/bioc/html/bsseq.html
ImageJ		https://imagej.nih.gov/ij/
GraphPad Prism v9.4.1		https://www.graphpad.com/
Avizo		http://www.vsg3d.com/
ITK-SNAP		http://itksnap.org/
PANTHER Gene Ontology (v17.0)		http://www.pantherdb.org/tools/compareToRefList.jsp
RRHO2	(Cahill et al., 2018); (Plaisier et al., 2010)	https://github.com/RRHO2/RRHO2

866
867
868
869
870

Contact for Reagent and Resource Sharing

Requests for reagents and resources should be directed toward the Lead Contact, Harrison Gabel (gabelh@wustl.edu).

871 Experimental Model and Subject Details

872 Animal Husbandry

873 All animal protocols were approved by the Institutional Animal Care and Use Committee and the
874 Animal Studies Committee of Washington University in St. Louis, and in accordance with
875 guidelines from the National Institutes of Health (NIH). Mice were housed in a room on a 12:12
876 hour light/dark cycle, with controlled room temperature (20-22°C) and relative humidity (50%).
877 Home cages (36.2 x 17.1 x 13 cm) were individually ventilated and supplied with corncob
878 bedding and standard laboratory chow (PicoLab Irradiated Rodent Diet 5053) and water unless
879 otherwise specified. For experiments of progressive weight gain, male and female animals
880 (P900L n=18, 8 male, 10 female; WT n=24, 12 male, 12 female) were given free access to the
881 Tekkad High Fat Diet (Envigo; TD.88137; 42% Calories from Fat) instead of standard laboratory
882 chow from 10-30 weeks of age. During this time, mice were weighed weekly. At 30 weeks of
883 age, mice were single housed, and food was weighed every two days for a total of six days (3
884 timepoints) to measure food consumption. Unless otherwise specified, all mice were group-
885 housed and adequate measures were taken to minimize animal pain or discomfort.

886

887 **Transgenic animals**

888 The DNMT3A P900L mouse model was generated using single guide RNAs (sgRNAs) to create
889 a C→T substitution at chr12:3,907,719 (GRCm38/mm10 assembly). This mutation changed the
890 proline CCG codon into a leucine CTG codon (Supplemental Figure 1A). sgRNAs were cloned
891 into the pX330 Cas9 plasmid (Addgene), and then transfected into N2A cells. Validation was
892 done using the T7 enzyme assay by the Washington University School of Medicine Transgenic
893 Vectors Core. sgRNAs were transcribed *in vitro* using MEGAShortScript (Ambion), and Cas9
894 mRNA was *in vitro* transcribed, G-capped and poly-A tailed using the mMessageMachine kit
895 (Ambion). mRNA of the sgRNA and Cas9 were then injected into hybrid C57Bl/6J x CBA
896 fertilized eggs at the mouse genetics core at Washington University School of Medicine.
897 Founders were deep sequenced at expected cut sites to identify which alleles were present, and
898 deep sequencing analyses of four kilobases surrounding the targeted region was used to
899 ensure no off-target recombination events occurred. Founders were then crossed to C57BL6/J
900 females (JAX Stock No. 000664) for 5-10 generations before experimental analysis.

901

902 To generate experimental animals, *Dnmt3a*^{R878H/+} (R878H) or *Dnmt3a*^{P900L/+} (P900L) male mice
903 were crossed with C57BL6/J females (JAX Stock No. 000664). R878H and P900L females were
904 not used for breeding to avoid social differences in mothering from mutant dams. Mice were
905 genotyped with ear-, tail-, or toe- DNA by PCR for either R878H or P900L mutations. Mice were
906 weighed at a variety of timepoints to assess growth.

907

908 **Method Details**

909 **P900L Genotyping**

910 To genotype for the P900L mutation, ear-, tail-, or toe- DNA was amplified using primers
911 designed around the P900L mutation (F:AGAGGGGCATTTATGGATGA, R:
912 GAGGGGCCTATTTTGCTTTT). The 706bp PCR product could then be Sanger Sequenced
913 (Supplemental Figure 1A) or digested using *Msp*a1I for an extended 3-hour digestion time
914 followed by the standard heat-shock inactivation. The wild-type sequence is susceptible to
915 restriction enzyme digestion, leaving a 285bp and 421bp fragments, whereas the P900L
916 mutation is not digested and will remain at 706bp (Supplemental Figure 1B).

917

918 **Bone length measurements**

919 We chose to quantify long bones that may directly relate to the height phenotype seen in
920 patients. Femurs were dissected from 30–35-week-old mice (P900L n=18, 10 male, 8 female;
921 WT n=16, 9 male, 7 female) and scanned using a Faxitron Model UltraFocus100 Digital
922 Radiography system at the Washington University Musculoskeletal Research Center. Image
923 analysis was done using Faxitron Vision Software (Version 2.3.1). When analyzed with a 2-way
924 ANOVA, there was no significant sex effect. Bone lengths were also measured from dissected
925 femurs using a Vernier caliper, which yielded similar results (data not shown).

926

927 **Craniofacial morphological analyses**

928 A total of 16 sex-matched littermate paired mice (P900L n=8, 4 male, 4 female; WT n=8, 4 male,
929 4 female) at 30-35 weeks of age were fixed with intracardiac perfusions of 4%
930 paraformaldehyde. Whole mouse heads were scanned using a Scanco μ CT40 machine at the
931 Musculoskeletal Research Center at Washington University in St. Louis. Image processing was
932 performed as previously described (Christian et al., 2020; Hill et al., 2013). Briefly, CT images
933 were converted to 8-bit and surface reconstructions were acquired in Avizo
934 (<http://www.vsg3d.com/>). 35 landmarks were collected from surface reconstructions of the
935 cranium and mandible using Avizo. Principal components were identified from generalized
Procrustes analysis in Geomorph package in R and Morphologika software as previously

937 described (Hill et al., 2013). To identify specifically altered linear distances, landmark
938 coordinates were natural log-transformed and analyzed with linear regression using Euclidean
939 Distance Matrix Analysis (EDMA).

940

941 **EchoMRI to measure body composition**

942 Fat and lean mass measures of live WT and P900L mice were measured with whole-body
943 quantitative magnetic resonance using an EchoMRI Body Composition Analyzer at the
944 Washington University Diabetes Research Center. Experiments were performed as previously
945 described (Nixon et al., 2010). Briefly, animals of 30-35 weeks of age (P900L n=15, 8 male, 7
946 female; WT n=17, 10 male, 7 female) were placed in a plastic cylinder tube with a solid insert to
947 limit movement. Signal in response to a low-intensity electromagnetic field was used to measure
948 the relaxation of spin curves, allowing for the quantification of fat and lean tissue volume.
949 Canola oil was used to standardize measurements between different recording days.

950

951 **Magnetic Resonance Imaging (MRI) acquisition and Diffusion Tensor Imaging (DTI)** 952 **analysis**

953 A total of twenty-four animals were used for P900L experiments (WT n=12, 6 males, 6 females;
954 P900L n=12, 6 males, 6 females), and twenty-four animals for R878H experiments (WT n=12, 6
955 males, 6 females; R878H n=12, 6 males, 6 females). Imaging and analysis were performed as
956 described previously (Chen et al., 2021). In brief, isoflurane-anesthetized animals were scanned
957 with a small-animal MR scanner built around an Oxford Instruments 4.7T horizontal-bore
958 superconducting magnet equipped with an Agilent/Varian DirectDrive™ console. Data were
959 collected using a laboratory-built actively decoupled 7.5-cm ID volume coil (transmit)/1.5-cm OD
960 surface coil (receive) RF coil pair. Mouse respiratory rate and body temperature (rectal probe)
961 were measured with a Small Animal Instruments (SAI, Stony Brook, NY) monitoring and gating
962 unit.

963

964 T2-weighted trans-axial images (T2W), collected with a 2D fast spin-echo multi-slice (FSEMS)
965 sequence, were used for structural and volumetric analyses. Diffusion Tensor Imaging (DTI),
966 which measures the directional movement of water along and perpendicular to axons (fractional
967 anisotropy: FA), provided a measure of white-matter track integrity. DTI data were collected
968 using a multi-echo, spin-echo diffusion-weighted sequence with 25-direction diffusion encoding,
969 max b-value = 2200 s/mm², as described previously (Chen et al., 2021). Two echoes were
970 collected per scan, with an echo spacing of 23.4 ms, and combined offline to increase signal-to-
971 noise ratio (SNR), resulting in a SNR improvement of ~1.4x compared with a single echo.

972

973 DTI data were analyzed as described previously (Chen et al., 2021) according to the standard
974 MR diffusion equation (Stejskal & Tanner, 1965) using purpose-written MatLab software.
975 Eigenvalues ($\lambda_1, \lambda_2, \lambda_3$) corresponding to the diffusion coefficients in three orthogonal directions,
976 and parametric maps of apparent diffusion coefficient (ADC), axial diffusion (D_{axial}), radial
977 diffusion (D_{radial}), and fractional anisotropy (FA) were calculated according to standard methods
978 (Basser & Pierpaoli, 2011; Mori S & Tournier J-D, 2014). Parametric maps were converted into
979 NIfTI (.nii) files for inspection and segmentation using ITK-SNAP (www.itksnap.org).
980 Segmentation was performed blinded to strain, sex, or genotype, and consistency was
981 assessed by re-segmenting blinded data files.

982

983 **Behavioral Analyses**

984 Mice for behavioral testing were housed in mixed genotype home cages with 2-5 animals per
985 cage, and all tests were performed during the light cycle. All experimenters were female and
986 were blinded to genotype during testing. For increased experimental rigor and reproducibility,

987 we used separate cohorts of mice to ensure quality and consistency in any observed
988 phenotypes. Adult testing was performed when mice were 2-4 months of age.

989

990 *Maternal Isolation-Induced Ultrasonic Vocalizations*

991 Pup ultrasonic vocalization (USV) measurements were performed to assess early social
992 communicative behavior as previously described (Chen et al., 2021). Ninety-seven animals
993 were used for P900L experiments (n=47 WT, 19 males and 28 females; n=50 P900L, 30 males
994 and 20 females), and ninety-two animals were used for R878H experiments (n=51 WT, 24
995 males, 27 females; n=41 R878H, 19 males and 22 females). Recordings were done at postnatal
996 days 5, 7, and 9. In brief, adults were removed from the nest and home-cages were placed in a
997 warming box (~33°C) 10 minutes before recording began. Body temperature was recorded
998 immediately before placing pups in a dark, enclosed chamber for 3-minute recordings. Following
999 the USV recording, pups were weighed and returned to their nest. Frequency sonograms were
1000 prepared and analyzed in MATLAB as previously described (Chen et al., 2021; Christian et al.,
1001 2020). Within-subjects repeated measures ANOVA were used to assess significance, and no
1002 significant differences occurred between sexes for any vocalization measures, therefore data
1003 were combined between sexes.

1004

1005 *Marble burying*

1006 WT (n=13; 8 male, 5 female) and litter matched P900L (n=13; 8 male, 5 female) mice were used
1007 for marble burying as previously described (Christian et al., 2020). In brief, 8-week-old mice
1008 were placed in a transparent enclosure (28.5 cm x 17.5 cm x 12 cm) with clean aspen bedding
1009 and 20 dark blue marbles evenly spaced in a 4 x 5 grid on top of the bedding. Animals were
1010 allowed to explore freely for 30 minutes, and the number of buried marbles were counted every
1011 5 minutes by two independent blinded observers. Marbles were considered “buried” if they were
1012 at least two-thirds covered by bedding. Enclosure and marbles were cleaned thoroughly
1013 between animals. Data was analyzed with a within-subjects repeated measured ANOVA, and
1014 no sex effect was observed so data was combined between sexes.

1015

1016 *3-Chamber social approach*

1017 Eighteen litter-matched animals that were 10-12 weeks old were used in the 3-chamber social
1018 approach assay (P900L n=9, 5 male, 4 female; WT n=9, 4 male, 5 female) as previously
1019 described (Manno et al., 2020). Briefly, mice were acclimated to a clear acrylic rectangular
1020 apparatus (60 cm x 40.5 cm), which was separated into three chambers by walls with sliding
1021 doors (6 cm x 6 cm). The apparatus was placed in an isolated, quiet room with low light (270
1022 lux) to minimize stress. Both side chambers contained an inverted cup. Testing consisted of
1023 three 10-minute phases: during the first phase, the mouse freely explored all chambers, in the
1024 second phase a conspecific mouse was added to one of the cups (mouse vs. object), and in the
1025 third phase a novel conspecific was added to the remaining empty cup (novel vs. familiar).
1026 During all phases, the test mouse was allowed to freely explore, and all stimulus mice were sex-
1027 matched conspecifics. A digital video camera was used to record sessions, location of mice in
1028 the apparatus was analyzed. Between experimental animals, 70% ethanol was used to clean
1029 the apparatus. As mice rapidly habituate to this task (Manno et al., 2020), only the first 5
1030 minutes of each phase was used for analysis.

1031

1032 *Social Dominance Tube Test*

1033 Tube test was conducted to assess social hierarchy behavior as previously described (Chen et
1034 al., 2021). For P900L experiments, 94 animals were used (n=47 WT, 24 males and 23 females;

1035 n=47 P900L, 24 males and 23 females) across three experimental cohorts, and one cohort of
1036 34 mice was used for R878H experiments (n=17 WT, 9 males, 8 females; n=17 WT, 9 males, 8
1037 females). In brief, mice were allowed to learn to traverse the clear acrylic tube apparatus on
1038 days 1 and 2 of the task. On days 3-5, sex-matched pairs of WT and mutant mice were tested
1039 on dominance bouts, avoiding cage mate pairings. A new WT-mutant pairing was used each
1040 day, allowing for three distinct matchups for each animal. During bouts, animals were allowed to
1041 enter the tubes while separated from each other with an acrylic divider. A bout begins when the
1042 divider was removed and concluded when one mouse fully backed out of the tube or when 2
1043 minutes passed. The animal remaining in the tube was considered the winner of the bout
1044 (dominant) and the animal that exited the tube was the loser (submissive). Active wins were
1045 defined as the winner pushing the other animal from the tube, whereas passive wins were
1046 defined as the winner refusing to move and the loser backing out of the tube. The tube was
1047 cleaned with a 0.02% chlorhexidine solution between bouts. Bout recordings were scored by a
1048 blinded observer. A two-tailed binomial test was performed on numbers of bouts won, with a null
1049 hypothesis that 50% of bouts would be won by each genotype.

1050

1051 *Novel Object Recognition – Tactile*

1052 Novel Object Recognition-Tactile (NORT) was used to measure general and tactile associative
1053 memory adapted from previous work (Orefice et al., 2019; Orefice et al., 2016). Briefly, the task
1054 consisted of five consecutive days including two initial habituation trials, NORT testing, a third
1055 habituation trial, and NOR testing. During habituation trials, mice were allowed to freely explore
1056 the empty acrylic apparatus (26 x 26 cm or 40 x 40 cm) for 10 minutes under white light (75-100
1057 lux). During NORT testing, the mice received a learning trial to freely explore two matching
1058 acrylic 4cm cubes that were either both smooth or both textured. Following a 5-minute inter-trial
1059 interval (ITI) in which the animals were removed to holding cages, the mice received a 3-minute
1060 test trial during which one of the cubes was replaced with a novel cube identical in appearance
1061 to the original object but with different tactile properties (smooth vs. textured). NOR was
1062 conducted the same as NORT except the objects differed visually, tactilely, and in size and
1063 materials, and the ITI was 50 minutes. The objects consisted of a ½ inch diameter white PVC
1064 standing pipe measuring 14 cm tall surrounded by a metal spiral and a 3D-printed blue block
1065 measuring 14.4 cm x 5 cm x 2.5 cm. For both NORT and NOR, object type and side on which
1066 the novel object was presented was counterbalanced across groups. The movement of the mice
1067 was tracked with ANY-maze Software (Stoelting, Co.). The outcomes analyzed included total
1068 distance traveled and time spent investigating the objects, defined as the nose within 10 mm
1069 zone surrounding the object and pointing towards the object, excluding any time the mouse was
1070 climbing on the object. All objects and the apparatus were cleaned with 0.02% chlorhexidine
1071 between trials.

1072

1073 *One-hour locomotor activity*

1074 P900L (n=21, 11 male and 10 female) and litter-matched WT (n=21, 10 male and 11 female)
1075 mice were used for the remainder of behavioral tests, which were performed by the Intellectual
1076 and Developmental Disabilities Research Center Animal Behavior Subunit at Washington
1077 University in St. Louis. Locomotor activity was measured in a transparent polystyrene enclosure
1078 (47.6 cm x 25.4 cm x 20.6 cm) by measuring photobeam breaks, as previously described

1079 (Maloney, Yuede, et al., 2019). Total ambulatory movement, vertical rearing behavior, and time
1080 spent in a 33 cm x 11 cm central zone were measured.

1081

1082 *Sensorimotor battery*

1083 Walking initiation, balance (ledge and platform tests), volitional movement (pole and inclined
1084 screens), and strength (inverted screen) were measured as described previously (Chen et al.,
1085 2021). For the walking initiation test, mice were placed on the surface in the center of a 21 cm x
1086 21 cm square marked with tape and the time for the mouse to leave the square was recorded.
1087 During the balance tests, the time the mouse remained on an elevated plexiglass ledge (0.75
1088 cm wide) or small circular wooden platform (3.0 cm in diameter) was recorded. During the Pole
1089 test, mice were placed at the top of a vertical pole pointing upwards, and the time for the mouse
1090 to turn and descend the pole was recorded. During the inclined screen tests, the mouse was
1091 placed head-down on an elevated mesh grid, and the time to climb up the grid was recorded.
1092 During the inverted screen test, a mouse was placed on an elevated mesh grid, which was then
1093 inverted 180°, and the time to fall was measured. Tests lasted for 1 minute, except for the pole
1094 test which lasted 2 minutes. Data used for analysis are an average of two trials done on
1095 subsequent days.

1096

1097 *Continuous and accelerating rotarod*

1098 Balance and coordination were assessed using the rotarod test (Rotamex-5, Columbus
1099 Instruments, Columbus, OH) as previously described (Maloney, Yuede, et al., 2019), using both
1100 constant rotation (5 rpm, 60 second maximum) and acceleration rotation (5-20 rpm, 180 second
1101 maximum) trials. Three sessions of testing consisting of two trials each were conducted, and
1102 trials were averaged. To focus the task on coordination rather than learning, testing sessions
1103 were separated by 4 days.

1104

1105 *Morris water maze*

1106 To assess spatial learning, we performed the Morris Water Maze, consisting of cued trials, place
1107 trials, and probe trials as previously described (Maloney, Yuede, et al., 2019). Animals were
1108 placed in a large water-filled pool, and time and distance to reach an escape platform were
1109 measured (ANY-maze, Stoelting). Maximum trial duration was 1 minute. During cued trials,
1110 there was a visible escape platform that was moved to new locations for each trial, and the mice
1111 experienced 4 trials per day (separated by 30-minute inter-trial-intervals) across 2 days.
1112 Performance was analyzed in 2-trial blocks, with trials averaged. Three days later, animals were
1113 tested in place trials in which the escape platform was submerged in a consistent location, and
1114 there were numerous distal visual cues available. Place trials occurred daily for 5 days,
1115 consisting of 2 blocks of 2 consecutive trials. Trials within blocks were separated by a 30-
1116 second interval, and blocks were separated by 2 hours. Mice were released in different areas of
1117 the maze and required to use visual cues to find the hidden platform. Trial data were averaged
1118 across the trials within each day. One hour after the final place trial occurred, the probe trial took
1119 place, in which the platform was removed entirely. The mouse was released from the quadrant
1120 opposite to the learned platform location and allowed to swim in the task for one minute. Time
1121 spent in each quadrant, and the number of crossings over the zone the platform was previously
1122 in were recorded.

1123

1124 *Elevated plus maze*

1125 Elevated plus maze tests were done as previously described (Maloney, Rieger, et al., 2019). In
1126 brief, the elevated apparatus contains a central platform (5.5 cm x 5.5 cm) with four arms
1127 extending from the central platform (each 36 cm x 6.1 cm). Two opposing arms were open and
1128 two have 15 cm tall opaque Plexiglas walls. Test sessions were conducted in a dimly lit
1129 environment with in which the mouse was able to freely explore the apparatus for 5 minutes.

1130 Position was measured with beam-breaks and time, distance, and entries into each zone were
1131 recorded and analyzed (MotoMonitor, Kinder Scientific).

1132

1133 *Conditioned fear*

1134 Fear conditioning was performed as previously described (Maloney, Rieger, et al., 2019).
1135 Briefly, mice were habituated to an acrylic chamber (26 cm x 18 cm x 18 cm) that contained a
1136 metal grid floor, a LED light which remained on during trials, and a chamber odorant. During the
1137 training day, baseline measurements of freezing behavior were collected for 2 minutes. Then,
1138 once per minute, three training rounds occurred in which a 20-second 80 dB tone sounded for
1139 20 seconds. During the last 2 seconds of the tone (conditioned stimulus) a 1.0 mA foot-shock
1140 (unconditioned stimulus) occurred. The next day, contextual fear was tested, in which the
1141 animals were placed in the same chamber with the same odorant with the testing light
1142 illuminated but no tones or shocks delivered. The following day, cued fear was tested, in which
1143 the animals were placed in a new opaque box with a new odorant. After a 2-minute baseline
1144 period with no tone, the same 80 dB tone was played for the remainder of the 8-minute trial.
1145 During all trials, freezing behavior were recorded and analyzed.

1146

1147 *Statistical analysis for behavioral tests*

1148 Behavioral data were analyzed and plotted using GraphPad Prism 9.4.1. No consistent
1149 genotype by sex interaction effects were observed for any behavioral tests, therefore data were
1150 collapsed across sex. Statistical testing was performed using planned assay-specific methods,
1151 such as using unpaired Student's T-Tests for single parameter comparisons between
1152 genotypes, and within-subjects two-way or three-way repeated-measures ANOVA for
1153 comparisons across timepoints. Individual timepoints within repeated measures tests were
1154 evaluated using Sidak's multiple comparisons test. Unless otherwise noted, bar graphs and line
1155 graphs indicate mean \pm SEM.

1156

1157 **DNMT3A Protein and RNA Expression**

1158 Cortex tissue from P900L and WT animals (2 weeks old) were dissected in ice-cold PBS, flash
1159 frozen with liquid nitrogen, and stored at -80°C . Half of the cortex was used for protein
1160 expression measurement with western blotting, and the other half was used for RNA expression
1161 via RT-qPCR. Expression was assessed at 2 weeks of age because this is a timepoint with high
1162 postnatal expression.

1163

1164 *Western Blotting*

1165 Western blotting was performed as previously described (Christian et al., 2020). WT and P900L
1166 (n=8/genotype, 4 males, 4 females) half-cortexes were homogenized with protease inhibitors
1167 (Buffer: 10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl_2 , 1mM DTT, 10mM EDTA), and 1%
1168 SDS was added prior to boiling the samples for 10 minutes at 95°C . Subsequently, samples
1169 were spun at 15,000g for 10 minutes, and supernatant was run through a Wizard Column
1170 (Fisher, Wizard Minipreps Mini Columns, PRA7211), and protein concentration was measured
1171 using a Bradford assay. Samples were diluted in LDS sample buffer with 5% β -mercaptoethanol
1172 and boiled for 5 minutes before being run on a gel. An 8% acrylamide gel was used, and
1173 samples were run for 60 minutes at 125V before being transferred to a nitrocellulose
1174 membrane. Blots were blocked for 1 hour at room temperature in TBS-T with 3% bovine serum
1175 albumin, then immunostained with anti-DNMT3A (Abcam, 1:1000, ab13888) or anti- α -Tubulin
1176 (Abcam, 1:1000, ab52866) for 12-16 hours at 4°C . After washing membranes, they were
1177 incubated with secondary antibodies for 1 hour at room temperature in light-protected boxes
1178 (IRDye 800CW Goat anti-Rabbit, or IRDye 800CW Goat anti-Mouse, LI-COR Biosciences,
1179 1:15,000, product numbers: 926-32211 and 926-32210 respectively). Primary and secondary
1180 antibodies were diluted in 3% Bovine Serum Albumin in TBS-T. Blots were imaged using the

1181 LiCOR Odyssey XCL system and quantified using Image Studio Lite software (LI-COR
1182 Biosciences). DNMT3A and α -Tubulin levels were normalized to a standard curve, and protein
1183 levels are expressed as normalized DNMT3A values divided by normalized α -Tubulin values to
1184 enable comparison of DNMT3A levels between blots. Significance was assessed using an
1185 unpaired Student's T-Test.

1186

1187 *qRT-PCR*

1188 RNA from WT and P900L (n=5/genotype, 3 males, 2 females) half-cortexes were isolated using
1189 the AllPrep DNA/RNA kits (QIAGEN, 80284), and RNAs were reverse transcribed using the
1190 using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). *DNMT3A* and
1191 *ACTB* were measured by qPCR using the Power SYBR™ Green PCR Master Mix and primers
1192 for *ACTB* (F:AAGGCCAACCGTGAAAAGAT, R:GTGGTACGACCAGAGGCATAC) or *DNMT3A*
1193 (F:GGCCTTCTCGACTCCAGATG, R:TTCCTCTTCTCAGCTGGCAC). The Ct of each primer
1194 set in each sample was calculated, and relative quantity was determined by comparing to a
1195 standard curve and then normalizing the *DNMT3A* signal to the *ACTB* signal.

1196

1197 **Whole Genome Bisulfite sequencing**

1198 *Global methylation across brain regions*

1199 300ng of DNA was isolated from brain tissue from 8-week animals
1200 (n=2/sex/genotype/mutation/region) using the AllPrep DNA/RNA kit (QIAGEN, 80284). DNA
1201 was then fragmented for 45 seconds with the Covaris S220 sonicator (10% Duty Factory, 175
1202 Peak Incidence Power, 200 cycles per burst, milliTUBE 200 μ L AFA Fiber). To select for long
1203 DNA inserts, DNA was purified using 0.7 volumes of Agencourt Beads. A small amount of
1204 Lambda DNA was spiked in to allow for estimation of non-conversion rates. To prepare bisulfite
1205 DNA libraries, we used the Tecan Ovation Ultralow Methyl-Seq Kit (Tecan, 0335-32) and the
1206 Epitect Bisulfite Kit (Qiagen, 59824). Alternate bisulfite conversion cycling conditions were used
1207 to ensure lowest possible non-conversion rate ([95°C, 5 min; 60°C, 20 min] x 4 cycles, 20°C
1208 hold). Libraries were PCR amplified 11-13 cycles and pooled for low-depth sequencing at the
1209 Washington University in St. Louis Center for Genomic Science. Libraries were sequenced
1210 using a MiSeq 2x150 and sequenced at an average depth of 0.018x genomic coverage
1211 (average 0.2M reads per sample). Sequencing data were processed as described below, and
1212 genome-wide averages of mCA and mCG were analyzed using a paired Student's T-Test with
1213 Bonferroni correction.

1214

1215 *Deep sequencing of cortical DNA methylation*

1216 50ng of DNA isolated from a total of sixteen 8-week cortex samples
1217 (n=2/sex/genotype/mutation) and fragmented for 45 seconds using the Covaris E220 sonicator
1218 (10% Duty Factory, 175 Peak Incidence Power, 200 cycles per burst, milliTUBE 200 μ L AFA
1219 Fiber) and purified using 0.7 volumes of SPRISelect Beads (Beckman Coulter Life Sciences). A
1220 small amount of Lambda DNA was spiked in to allow for estimation of non-conversion rates.
1221 DNA was then bisulfite converted using the EZ DNA Methylation-Direct Kit (Zymo Research
1222 Corporation, D5020) using extended bisulfite conversion incubation to ensure lowest possible
1223 non-conversion rates (98°C, 8 min; 64°C, 4 hours 15 min). Samples were either stored
1224 overnight at -20°C, or libraries were immediately prepared using the Accel-NGS Methyl-Seq
1225 DNA Library Kit (Swift, 30024) with combinatorial dual indexes (Swift, 38096) as instructed,
1226 using 10 cycles of final amplification. Libraries were pooled and sequenced at the Genome
1227 Technology Access Center at the Washington University McDonnell Genome Institute using the
1228 NovaSeq 6000 2x150. An average sequencing depth of 10x genomic coverage (average 144M
1229 reads per sample) were obtained per sample.

1230

1231 *Whole genome bisulfite analysis*

1232 Analysis of bisulfite sequencing was performed as described previously (Christian et al., 2020;
1233 Clemens et al., 2019). Reads were adapter-trimmed, mapped to mm9, deduplicated, and called
1234 for methylation using BS-seeker2 (W. Guo et al., 2013). Bedtools map -o sum was used to
1235 assess methylation across regions, summing the number of reads mapped to Cs (interpreted as
1236 mC after bisulfite conversion) and then dividing by the sum of Cs and Ts (indicating C) at that
1237 region. %mC values from biological replicates were averaged together. Though our methods
1238 should maximize the amount of efficient bisulfite conversion, a small percentage of
1239 unmethylated cytosines can be called as methylated due to nonconversion (0.2-0.3%). To
1240 adjust for nonconversion rate, regions were adjusted by the % methylation measured in Lambda
1241 spike-ins per sample, similar to previous analysis (Lister et al., 2013). If corrected region values
1242 were below 0, the %mC value was set to 0. Due to background nonconversion, lowly
1243 methylated regions (e.g., mCA at CpG islands or promoters) are not expected to show the same
1244 percentage reduction in methylation as higher mCA regions.

1245 *Differentially methylated region detection*

1246 We used BSmooth (Hansen et al., 2012) on four biological replicates of P900L or R878H and
1247 their sex-matched WT littermates to call differential CpG methylated regions. CG sites were
1248 then filtered, requiring >2x genomic coverage in all replicates. Differentially methylated regions
1249 (DMRs) were called using a statistical threshold of t-stat >2.0, requiring length >100 bp, and
1250 biological replicate consistency (i.e. for hypomethylated regions, all WT mCG/CG values must
1251 be higher than mutant mCG/mCG values). Data fit the assumptions and requirements for
1252 BSmooth and fisher's exact testing. Resampling for overlap analysis was done using bedtools
1253 shuffle.
1254

1255 **Chromatin immunoprecipitation sequencing**

1256 *Chromatin immunoprecipitation library generation*

1257 Chromatin immunoprecipitation was performed as previously described (Clemens et al., 2019).
1258 Cerebral cortex was dissected on ice in PBS from DNMT3A mutants and their WT littermates at
1259 8-weeks old (n=2/sex/genotype/mutation; a total of 4 WT and 4 mutants in P900L litters, and a
1260 total of 4 WT and 4 mutants in R878H litters). The tissue was flash-frozen in liquid nitrogen and
1261 stored at -80°C. Chromatin was fragmented with the Covaris E220 sonicator (5% Duty Factory,
1262 140 Peak Incidence Power, 200 cycles per burst, milliTUBE 1mL AFA Fiber). ChIP was
1263 performed with H3K27ac antibody (0.1µg; Abcam, ab4729) and libraries were generated using
1264 Accel-NGS 2S Plus DNA Library Kit (Swift Biosciences). Pooled libraries were sequenced using
1265 a NovaSeq 6000 with the Genome Technology Access Center at Washington University in St.
1266 Louis, typically yielding 20-50 million (average: 34 million) single-end reads per sample.

1267 *Chromatin immunoprecipitation analysis*

1268 ChIP sequencing analysis was performed as previously described (Clemens et al., 2019). In
1269 brief, reads were mapped to mm9 with bowtie2, and deduplicated with picardtools
1270 MarkDuplicates. Bedtools coverage -counts was used to assess H3K27ac signal at the various
1271 genomic regions examined. edgeR was then used to determine differential H3K27ac signal
1272 between WT and mutant animals. Data were visualized using the UCSC genome browser
1273 (Haeussler et al., 2019).
1274

1275 **RNA sequencing**

1276 *RNA sequencing library generation*

1277 Total RNA isolation was carried out as previously described (Clemens et al., 2019). In brief,
1278 cerebral cortex was dissected in ice-cold PBS from P900L or R878H mutants and their
1279

1280 respective WT littermates at 8 weeks of age (n=7 pairs, 3 male, 4 female). Cortex was lysed in
1281 RLT buffer and RNA was isolated using the AllPrep DNA/RNA kit (QIAGEN, 80284). RNA
1282 libraries were generated from 250ng of RNA with NEBNext Ultra Directional RNA Library Prep
1283 Kit for Illumina (NEB) using a modified amplification protocol (37°C, 15 minutes; 98°C, 30
1284 seconds; [98°C, 10 seconds; 65°C, 30 seconds; 72°C, 30 seconds]x13; 72°C, 5 minutes; 4°C
1285 hold). RNA libraries were pooled at a final concentration of 10nM and sequenced using Illumina
1286 NextSeq-High 1x75bp with the Center for Genome Sciences at Washington University in St.
1287 Louis, typically yielding 15-30 million single-end reads per sample.

1288

1289 *RNA sequencing analysis*

1290 RNA sequencing analysis was performed as previously described (Clemens et al., 2019).
1291 Briefly, raw FASTQ files were trimmed with Trim Galore and rRNA sequences were filtered and
1292 removed with Bowtie. Remaining reads were aligned to mm9 using STAR (Dobin et al., 2013),
1293 and uniquely mapping reads were converted to BED files and separated into intronic and exonic
1294 reads. These exonic BED files were used to assess gene counts using bedtools coverage -
1295 counts.

1296

1297 *Differential gene expression*

1298 DESeq2 was used to identify differentially expressed genes between mutants and their WT
1299 littermates. To control for batch, sex, and litter, paired analysis was done using a design = ~ pair
1300 + genotype, and contrasted by genotype for all analysis. Though all libraries were processed in
1301 groups that contained P900L and R878H pairs, P900L and R878H datasets were analyzed
1302 separately. Significantly dysregulated genes were called when $p_{adj} < 0.1$. Mutant-specific genes
1303 were defined as significantly regulated in one direction in one mutant, and either being
1304 unchanged (nominal p-value > 0.5) or regulated in the opposite direction in the other mutant.

1305

1306 *Defining shared TBRS genes*

1307 RNA-seq data in the DNMT3A KO/+ (n=7 pairs; 4 male, 3 female) from Christian et al., 2020
1308 were combined with P900L (n=7 pairs; 4 male, 3 female) and R878H (n=7 pairs; 4 male, 3
1309 female) datasets. All datasets were generated from 8-week cortex and processed using similar
1310 methods. Datasets were then combined, and littermate pairwise genotype comparisons were
1311 made using DESeq2 across all WT and mutant animals (design = ~ pair + group and contrasted
1312 by group; group defined as WT or mutant with no indication of origin dataset).

1313

1314 *PANTHER Gene Ontology analysis*

1315 Gene set enrichment analysis was done using the PANTHER Overrepresentation Test (Version
1316 17.0, Released 2022-02-22). Analyzed lists (e.g., significantly upregulated genes in the P900L
1317 mutant) were compared to a reference list of all expressed genes in our study (defined as genes
1318 with more than an average of 10 counts in both WT littermate datasets). Analysis identified
1319 PANTHER GO-slim Biological Process terms and used a Fisher test with FDR correction. A
1320 subset of the most significant PANTHER terms is shown in figures with full PANTHER results in
1321 Supplemental Table 2.

1322

1323 *Rank-rank hypergeometric overlap (RRHO) analysis*

1324 For each mutant-WT pair, a ranked gene list was created using a gene score calculated as -
1325 $\log_{10}(\text{p-value}) * \text{sign}(\log_2\text{Fold Change})$ using the DESeq2 results for that gene.
1326 RRHO2_initialize() was used to generate RRHO object, and RRHO2_heatmap() was used to
1327 generate a heatmap of overlapping genes between different mutants.

1328

1329 **Experimental design**

1330 Sample sizes were chosen based upon previously published studies using similar techniques.
1331 Statistical tests and exclusion criteria (values beyond 2 standard deviations of the group mean)
1332 were similar to that of previously published studies and indicated in the appropriate methods.
1333 For all animal experiments, experimenters were blinded to genotype during data collection. No
1334 treatment conditions were used, so no samples or animals were allocated to experimental
1335 groups and no randomization was needed. Tests that assume equal variance were only run if
1336 group variances were similar, otherwise alternative tests were used.

1337

1338 **Data availability statement**

1339 The data that support the findings of this study are available from the corresponding author
1340 upon request. DOIs for all published gene sets used in comparison and enrichment analysis:

1341 Lister et al. 2013: <https://doi.org/10.1126/science.1237905>

1342 Clemens et al. 2019: <https://doi.org/10.1016/j.molcel.2019.10.033>

1343 Christian et al. 2020: <https://doi.org/10.1016/j.celrep.2020.108416>

1344 Hamagami et al. 2023: <https://doi.org/10.1101/2023.02.17.528965>

1345 Bisulfite-seq, RNA-seq, and ChIP-seq are available on the NCBI GEO archive GSE225372.

1346 Reviewer token: wjngmaggwhvkrjkr.

1347

1348 **Acknowledgements:**

1349 We thank T. Ley and the TBRS community for reagents and discussion. We also thank J.
1350 Hoisington-Lopez and M. Crosby at the Center for Genome Sciences, GTAC for sequencing
1351 support, D. Wozniak and the IDDR@WUSTL Animal Behavior Subunit, C. Semenkovich and
1352 S. Adak at the Washington University Diabetes Research Center, M. Brodt and the Washington
1353 University Musculoskeletal Research Center, and M. Haywood for assistance landmarking
1354 skulls. We thank our funding sources: NIH-NICHD F31HD100098 (to D.C.B.); NIH-NICHD
1355 P50HD103525 (to the IDDR@WUSTL); and The Simons Foundation Autism Research
1356 Initiative, NIH-NIMH R01MH117405, and NIH-NINDS R01NS04102 (to H.W.G.).

1357

1358 **Author Contributions:**

1359 Conceptualization and Methodology, DCB and HWG; Formal Analysis, DCB, DYW, NH, XG,
1360 ABH, ABL, CAH, TP, AM, JG, JDD, SEM; Investigation, DCB, XZ, JRM, NH, RGS, KBM, XG,
1361 ABH, HZ, ABL, TP, SEM; Writing – Original Draft, DCB and HWG; Writing – Review & Editing,
1362 all authors.

1363

1364 **Supplemental Information**

1365 Supplemental Information includes three figures and two tables.

1366 **Table S1.** Detailed Statistical Methods and Outputs; Related to Figures 1-5, 7, S1-S3

1367 **Table S2.** Full table of significant PANTHER terms, Related to Figures 6, 7

1368

1369

1370 Akaba, Y., Shiohama, T., Komaki, Y., Seki, F., Ortug, A., Sawada, D., Uchida, W., Kamagata,
1371 K., Shimoji, K., Aoki, S., Takahashi, S., Suzuki, T., Natsume, J., Takahashi, E., &
1372 Tsujimura, K. (2022). Comprehensive Volumetric Analysis of Mecp2-Null Mouse Model for
1373 Rett Syndrome by T2-Weighted 3D Magnetic Resonance Imaging. *Frontiers in*
1374 *Neuroscience*, 16. <https://doi.org/10.3389/fnins.2022.885335>

1375 Allemang-Grand, R., Ellegood, J., Spencer Noakes, L., Ruston, J., Justice, M., Nieman, B. J., &
1376 Lerch, J. P. (2017). Neuroanatomy in mouse models of Rett syndrome is related to the

- 1377 severity of Mecp2 mutation and behavioral phenotypes. *Molecular Autism*, 8(1).
1378 <https://doi.org/10.1186/s13229-017-0138-8>
- 1379 Bartholomeusz, H. H., Courchesne, E., & Karns, C. M. (2002). Relationship Between Head
1380 Circumference and Brain Volume in Healthy Normal Toddlers, Children, and Adults.
1381 *Neuropediatrics*, 33(5), 239–241. <https://doi.org/10.1055/s-2002-36735>
- 1382 Bassar, P. J., & Pierpaoli, C. (2011). Microstructural and physiological features of tissues
1383 elucidated by quantitative-diffusion-tensor MRI. *Journal of Magnetic Resonance*, 213(2),
1384 560–570. <https://doi.org/10.1016/j.jmr.2011.09.022>
- 1385 Boxer, L. D., Renthal, W., Greben, A. W., Whitwam, T., Silberfeld, A., Stroud, H., Li, E., Yang,
1386 M. G., Kinde, B., Griffith, E. C., Bonev, B., & Greenberg, M. E. (2020). MeCP2 Represses
1387 the Rate of Transcriptional Initiation of Highly Methylated Long Genes. *Molecular Cell*,
1388 77(2), 294-309.e9. <https://doi.org/10.1016/j.molcel.2019.10.032>
- 1389 Cahill, K. M., Huo, Z., Tseng, G. C., Logan, R. W., & Seney, M. L. (2018). Improved
1390 identification of concordant and discordant gene expression signatures using an updated
1391 rank-rank hypergeometric overlap approach. *Scientific Reports*, 8(1).
1392 <https://doi.org/10.1038/s41598-018-27903-2>
- 1393 Chen, J., Lambo, M. E., Ge, X., Dearborn, J. T., Liu, Y., McCullough, K. B., Swift, R. G.,
1394 Tabachnick, D. R., Tian, L., Noguchi, K., Garbow, J. R., Constantino, J. N., Gabel, H. W.,
1395 Hengen, K. B., Maloney, S. E., & Dougherty, J. D. (2021). A MYT1L syndrome mouse
1396 model recapitulates patient phenotypes and reveals altered brain development due to
1397 disrupted neuronal maturation. *Neuron*, 109(23), 3775-3792.e14.
1398 <https://doi.org/10.1016/j.neuron.2021.09.009>
- 1399 Christian, D. L., Wu, D. Y., Martin, J. R., Moore, J. R., Liu, Y. R., Clemens, A. W., Nettles, S. A.,
1400 Kirkland, N. M., Papouin, T., Hill, C. A., Wozniak, D. F., Dougherty, J. D., & Gabel, H. W.
1401 (2020). DNMT3A Haploinsufficiency Results in Behavioral Deficits and Global Epigenomic
1402 Dysregulation Shared across Neurodevelopmental Disorders. *Cell Reports*, 33(8).
1403 <https://doi.org/10.1016/j.celrep.2020.108416>
- 1404 Clemens, A. W., & Gabel, H. W. (2020). Emerging Insights into the Distinctive Neuronal
1405 Methylome. In *Trends in Genetics* (Vol. 36, Issue 11, pp. 816–832). Elsevier Ltd.
1406 <https://doi.org/10.1016/j.tig.2020.07.009>
- 1407 Clemens, A. W., Wu, D. Y., Moore, J. R., Christian, D. L., Zhao, G., & Gabel, H. W. (2019).
1408 MeCP2 Represses Enhancers through Chromosome Topology-Associated DNA
1409 Methylation. *Molecular Cell*, 77(2), 279-293.e8.
1410 <https://doi.org/10.1016/j.molcel.2019.10.033>
- 1411 Co, M., Barnard, R. A., Jahncke, J. N., Grindstaff, S., Fedorov, L. M., Adey, A. C., Wright, K. M.,
1412 & O’Roak, B. J. (2022). Shared and Distinct Functional Effects of Patient-Specific Tbr1
1413 Mutations on Cortical Development. *Journal of Neuroscience*, 42(37), 7166–7181.
1414 <https://doi.org/10.1523/JNEUROSCI.0409-22.2022>
- 1415 Coe, B. P., Stessman, H. A. F., Sulovari, A., Geisheker, M. R., Bakken, T. E., Lake, A. M.,
1416 Dougherty, J. D., Lein, E. S., Hormozdiari, F., Bernier, R. A., & Eichler, E. E. (2019).
1417 Neurodevelopmental disease genes implicated by de novo mutation and copy number

- 1418 variation morbidity. *Nature Genetics*, 51(1), 106–116. [https://doi.org/10.1038/s41588-018-](https://doi.org/10.1038/s41588-018-0288-4)
1419 0288-4
- 1420 Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson,
1421 M., & Gingeras, T. R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*,
1422 29(1), 15–21. <https://doi.org/10.1093/bioinformatics/bts635>
- 1423 Duan, Y., Wang, S. H., Song, J., Mironova, Y., Ming, G. Li, Kolodkin, A. L., & Giger, R. J. (2014).
1424 Semaphorin 5A inhibits synaptogenesis in early postnatal- and adult-born hippocampal
1425 dentate granule cells. *ELife*, 3. <https://doi.org/10.7554/eLife.04390>
- 1426 Duyar, I., & Pelin, C. (2003). Body height estimation based on tibia length in different stature
1427 groups. *American Journal of Physical Anthropology*, 122(1), 23–27.
1428 <https://doi.org/10.1002/ajpa.10257>
- 1429 Emperle, M., Dukatz, M., Kunert, S., Holzer, K., Rajavelu, A., Jurkowska, R. Z., & Jeltsch, A.
1430 (2018). The DNMT3A R882H mutation does not cause dominant negative effects in
1431 purified mixed DNMT3A/R882H complexes. *Scientific Reports*, 8(1).
1432 <https://doi.org/10.1038/s41598-018-31635-8>
- 1433 Fazel Darbandi, S., Robinson Schwartz, S. E., Pai, E. L. L., Everitt, A., Turner, M. L., Cheyette,
1434 B. N. R., Willsey, A. J., State, M. W., Sohal, V. S., & Rubenstein, J. L. R. (2020).
1435 Enhancing WNT Signaling Restores Cortical Neuronal Spine Maturation and
1436 Synaptogenesis in Tbr1 Mutants. *Cell Reports*, 31(2).
1437 <https://doi.org/10.1016/j.celrep.2020.03.059>
- 1438 Fazel Darbandi, S., Robinson Schwartz, S. E., Qi, Q., Catta-Preta, R., Pai, E. L. L., Mandell, J.
1439 D., Everitt, A., Rubin, A., Krasnoff, R. A., Katzman, S., Tastad, D., Nord, A. S., Willsey, A.
1440 J., Chen, B., State, M. W., Sohal, V. S., & Rubenstein, J. L. R. (2018). Neonatal Tbr1
1441 Dosage Controls Cortical Layer 6 Connectivity. *Neuron*, 100(4), 831-845.e7.
1442 <https://doi.org/10.1016/j.neuron.2018.09.027>
- 1443 Feng, J., Chang, H., Li, E., & Fan, G. (2005). Dynamic expression of de novo DNA
1444 methyltransferases Dnmt3a and Dnmt3b in the central nervous system. *Journal of*
1445 *Neuroscience Research*, 79(6), 734–746. <https://doi.org/10.1002/jnr.20404>
- 1446 Gabel, H. W., Kinde, B., Stroud, H., Gilbert, C. S., Harmin, D. A., Kastan, N. R., Hemberg, M.,
1447 Ebert, D. H., & Greenberg, M. E. (2015). Disruption of DNA-methylation-dependent long
1448 gene repression in Rett syndrome. *Nature*, 522(7554), 89–93.
1449 <https://doi.org/10.1038/nature14319>
- 1450 Giacomani-Lozano, M., Meléndez-Ramírez, C., Martínez-Ledesma, E., Cuevas-Díaz Duran, R.,
1451 & Velasco, I. (2022). Epigenetics of neural differentiation: Spotlight on enhancers. In
1452 *Frontiers in Cell and Developmental Biology* (Vol. 10). Frontiers Media S.A.
1453 <https://doi.org/10.3389/fcell.2022.1001701>
- 1454 Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., Zhong, C., Hu, S., Le, T., Fan, G., Zhu,
1455 H., Chang, Q., Gao, Y., Ming, G. L., & Song, H. (2014). Distribution, recognition and
1456 regulation of non-CpG methylation in the adult mammalian brain. *Nature Neuroscience*,
1457 17(2), 215–222. <https://doi.org/10.1038/nn.3607>

- 1458 Guo, W., Fiziev, P., Yan, W., Cokus, S., Sun, X., Zhang, M. Q., Chen, P.-Y., & Pellegrini, M.
1459 (2013). BS-Seeker2: a versatile aligning pipeline for bisulfite sequencing data. *BMC*
1460 *Genomics*, 14(1), 774. <https://doi.org/10.1186/1471-2164-14-774>
- 1461 Haeussler, M., Zweig, A. S., Tyner, C., Speir, M. L., Rosenbloom, K. R., Raney, B. J., Lee, C.
1462 M., Lee, B. T., Hinrichs, A. S., Gonzalez, J. N., Gibson, D., Diekhans, M., Clawson, H.,
1463 Casper, J., Barber, G. P., Haussler, D., Kuhn, R. M., & Kent, W. J. (2019). The UCSC
1464 Genome Browser database: 2019 update. *Nucleic Acids Research*, 47(D1), D853–D858.
1465 <https://doi.org/10.1093/nar/gky1095>
- 1466 Hamagami, N., Wu, D. Y., Clemens, A. W., Nettles, S. A., & Gabel, H. W. (2023). NSD1
1467 deposits histone H3 lysine 36 dimethylation to pattern non-CG DNA methylation in
1468 neurons. *BioRxiv*.
- 1469 Han, K. A., Yoon, T. H., Shin, J., Um, J. W., & Ko, J. (2020). Differentially altered social
1470 dominance- and cooperative-like behaviors in Shank2- and Shank3-mutant mice.
1471 *Molecular Autism*, 11(1). <https://doi.org/10.1186/s13229-020-00392-9>
- 1472 Hansen, K. D., Langmead, B., & Irizarry, R. A. (2012). BSmooth: from whole genome bisulfite
1473 sequencing reads to differentially methylated regions. *Genome Biology*, 13(10).
1474 <https://doi.org/10.1186/gb-2012-13-10-R83>
- 1475 Hill, C. A., Martínez-Abadías, N., Motch, S. M., Austin, J. R., Wang, Y., Jabs, E. W.,
1476 Richtsmeier, J. T., & Aldridge, K. (2013). Postnatal brain and skull growth in an Apert
1477 syndrome mouse model. *American Journal of Medical Genetics, Part A*, 161(4), 745–757.
1478 <https://doi.org/10.1002/ajmg.a.35805>
- 1479 Huang, T. N., Chuang, H. C., Chou, W. H., Chen, C. Y., Wang, H. F., Chou, S. J., & Hsueh, Y.
1480 P. (2014). Tbr1 haploinsufficiency impairs amygdalar axonal projections and results in
1481 cognitive abnormality. *Nature Neuroscience*, 17(2), 240–247.
1482 <https://doi.org/10.1038/nn.3626>
- 1483 Huang, Y. H., Chen, C. W., Sundaramurthy, V., Słabicki, M., Hao, D., Watson, C. J., Tovy, A.,
1484 Reyes, J. M., Dakhova, O., Crovetti, B. R., Galonska, C., Lee, M., Brunetti, L., Zhou, Y.,
1485 Brown, K. T., Huang, Y., Cheng, X., Meissner, A., Valk, P. J. M., ... Goodell, M. A. (2022).
1486 Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the
1487 DCAF8 E3 Ubiquitin Ligase Adaptor. *Cancer Discovery*, 12(1), 220–235.
1488 <https://doi.org/10.1158/2159-8290.CD-21-0560>
- 1489 Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E., & Sasaki, H. (2004). *Essential*
1490 *role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting*.
1491 www.nature.com/nature
- 1492 Katano, T., Fukuda, M., Furue, H., Yamazaki, M., Abe, M., Watanabe, M., Nishida, K., Yao, I.,
1493 Yamada, A., Hata, Y., Okumura, N., Nakazawa, T., Yamamoto, T., Sakimura, K., Takao,
1494 T., & Ito, S. (2016). Involvement of Brain-Enriched Guanylate Kinase-Associated Protein
1495 (BEGAIN) in Chronic Pain after Peripheral Nerve Injury. *Eneuro*, 3(5), ENEURO.0110-
1496 16.2016. <https://doi.org/10.1523/ENEURO.0110-16.2016>
- 1497 Kozlenkov, A., Roussos, P., Timashpolsky, A., Barbu, M., Rudchenko, S., Bibikova, M., Klotzle,
1498 B., Byne, W., Lyddon, R., di Narzo, A. F., Hurd, Y. L., Koonin, E. v., & Dracheva, S. (2014).

- 1499 Differences in DNA methylation between human neuronal and glial cells are concentrated
1500 in enhancers and non-CpG sites. *Nucleic Acids Research*, 42(1), 109–127.
1501 <https://doi.org/10.1093/nar/gkt838>
- 1502 Kwon, H. S., Johnson, T. v., Joe, M. K., Abu-Asab, M., Zhang, J., Chan, C. C., & Tomarev, S. I.
1503 (2013). Myocilin mediates myelination in the peripheral nervous system through ErbB2/3
1504 signaling. *Journal of Biological Chemistry*, 288(37), 26357–26371.
1505 <https://doi.org/10.1074/jbc.M112.446138>
- 1506 Lavery, L. A., Ure, K., Wan, Y.-W., Luo, C., Trostle, A. J., Wang, W., Jin, H., Lopez, J., Lucero,
1507 J., Durham, M. A., Castanon, R., Nery, J. R., Liu, Z., Goodell, M., Ecker, J. R., Behrens, M.
1508 M., & Zoghbi, H. Y. (2020). Losing Dnmt3a dependent methylation in inhibitory neurons
1509 impairs neural function by a mechanism impacting Rett syndrome. *ELife*, 9.
1510 <https://doi.org/10.7554/eLife.52981>
- 1511 Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., Lucero, J.,
1512 Huang, Y., Dwork, A. J., Schultz, M. D., Yu, M., Tonti-Filippini, J., Heyn, H., Hu, S., Wu, J.
1513 C., Rao, A., Esteller, M., He, C., Haghghi, F. G., ... Ecker, J. R. (2013). Global epigenomic
1514 reconfiguration during mammalian brain development. *Science*, 341(6146).
1515 <https://doi.org/10.1126/science.1237905>
- 1516 Lue, N. Z., Garcia, E. M., Ngan, K. C., Lee, C., Doench, J. G., & Liau, B. B. (2022). Base editor
1517 scanning charts the DNMT3A activity landscape. *Nature Chemical Biology*.
1518 <https://doi.org/10.1038/s41589-022-01167-4>
- 1519 Makrides, N., Panayiotou, E., Fanis, P., Karaiskos, C., Lapathitis, G., & Malas, S. (2018).
1520 Sequential role of SOXB2 factors in GABAergic neuron specification of the dorsal midbrain.
1521 *Frontiers in Molecular Neuroscience*, 11. <https://doi.org/10.3389/fnmol.2018.00152>
- 1522 Maloney, S. E., Rieger, M. A., Al-Hasani, R., Bruchas, M. R., Wozniak, D. F., & Dougherty, J. D.
1523 (2019). Loss of CELF6 RNA binding protein impairs cocaine conditioned place preference
1524 and contextual fear conditioning. *Genes, Brain, and Behavior*, 18(7), e12593.
1525 <https://doi.org/10.1111/gbb.12593>
- 1526 Maloney, S. E., Yuede, C. M., Creeley, C. E., Williams, S. L., Huffman, J. N., Taylor, G. T.,
1527 Noguchi, K. N., & Wozniak, D. F. (2019). Repeated neonatal isoflurane exposures in the
1528 mouse induce apoptotic degenerative changes in the brain and relatively mild long-term
1529 behavioral deficits. *Scientific Reports*, 9(1). <https://doi.org/10.1038/s41598-019-39174-6>
- 1530 Manno, R., Witte, J., & Papouin, T. (2020). A Modular Setup to Run a Large Line of Behavioral
1531 Testing in Mice in a Single Space. *Current Protocols in Neuroscience*, 93(1).
1532 <https://doi.org/10.1002/cpns.102>
- 1533 Mo, A., Mukamel, E. A., Davis, F. P., Luo, C., Henry, G. L., Picard, S., Urich, M. A., Nery, J. R.,
1534 Sejnowski, T. J., Lister, R., Eddy, S. R., Ecker, J. R., & Nathans, J. (2015). Epigenomic
1535 Signatures of Neuronal Diversity in the Mammalian Brain. *Neuron*, 86(6), 1369–1384.
1536 <https://doi.org/10.1016/j.neuron.2015.05.018>
- 1537 Mori S, & Tournier J-D. (2014). *Introduction to diffusion tensor imaging and higher order models*
1538 (2nd ed.). Elsevier Science.

- 1539 Nguyen, S., Meletis, K., Fu, D., Jhaveri, S., & Jaenisch, R. (2007). Ablation of de novo DNA
1540 methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and
1541 shortened lifespan. *Developmental Dynamics*, 236(6), 1663–1676.
1542 <https://doi.org/10.1002/dvdy.21176>
- 1543 Nixon, J. P., Zhang, M., Wang, C., Kuskowski, M. A., Novak, C. M., Levine, J. A., Billington, C.
1544 J., & Kotz, C. M. (2010). Evaluation of a quantitative magnetic resonance imaging system
1545 for whole body composition analysis in rodents. *Obesity*, 18(8), 1652–1659.
1546 <https://doi.org/10.1038/oby.2009.471>
- 1547 Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999). DNA Methyltransferases Dnmt3a and
1548 Dnmt3b Are Essential for De Novo Methylation and Mammalian Development. In *Cell* (Vol.
1549 99).
- 1550 Orefice, L. L. L., Zimmerman, A. L. L., Chirila, A. M. M., Sleboda, S. J. J., Head, J. P. P., &
1551 Ginty, D. D. D. (2016). Peripheral Mechanosensory Neuron Dysfunction Underlies Tactile
1552 and Behavioral Deficits in Mouse Models of ASDs. *Cell*, 166(2), 299–313.
1553 <https://doi.org/10.1016/j.cell.2016.05.033>
- 1554 Orefice, L. L., Mosko, J. R., Morency, D. T., Wells, M. F., Tasnim, A., Mozeika, S. M., Ye, M.,
1555 Chirila, A. M., Emanuel, A. J., Rankin, G., Fame, R. M., Lehtinen, M. K., Feng, G., & Ginty,
1556 D. D. (2019). Targeting Peripheral Somatosensory Neurons to Improve Tactile-Related
1557 Phenotypes in ASD Models. *Cell*, 178(4), 867-886.e24.
1558 <https://doi.org/10.1016/j.cell.2019.07.024>
- 1559 Plummer, J. T., Gordon, A. J., & Levitt, P. (2016). The genetic intersection of
1560 neurodevelopmental disorders and shared medical comorbidities - relations that translate
1561 from bench to bedside. *Frontiers in Psychiatry*, 7(AUG).
1562 <https://doi.org/10.3389/fpsy.2016.00142>
- 1563 Polan, M. B., Pastore, M. T., Steingass, K., Hashimoto, S., Thrush, D. L., Pyatt, R., Reshmi, S.,
1564 Gastier-Foster, J. M., Astbury, C., & McBride, K. L. (2014). Neurodevelopmental disorders
1565 among individuals with duplication of 4p13 to 4p12 containing a GABA A receptor subunit
1566 gene cluster. *European Journal of Human Genetics*, 22(1), 105–109.
1567 <https://doi.org/10.1038/ejhg.2013.99>
- 1568 Ríos, A. S., Paula De Vincenti, A., Casadei, M., Aquino, J. B., Brumovsky, P. R., Paratcha, G.,
1569 & Ledda, F. (2022). Etv4 regulates nociception by controlling peptidergic sensory neuron
1570 development and peripheral tissue innervation. *Development (Cambridge, England)*,
1571 149(16). <https://doi.org/10.1242/dev.200583>
- 1572 Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R.,
1573 Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., & Ley, T. J. (2014).
1574 The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type
1575 DNMT3A by Blocking Its Ability to Form Active Tetramers. *Cancer Cell*, 25(4), 442–454.
1576 <https://doi.org/10.1016/j.ccr.2014.02.010>
- 1577 Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., Samocha, K. E., Cicek, A. E.,
1578 Murtha, M. T., Bal, V. H., Bishop, S. L., Dong, S., Goldberg, A. P., Jinlu, C., Keaney, J. F.,
1579 Klei, L., Mandell, J. D., Moreno-De-Luca, D., Poultney, C. S., Robinson, E. B., Smith, L., ...
1580 State, M. W. (2015). Insights into Autism Spectrum Disorder Genomic Architecture and

- 1581 Biology from 71 Risk Loci. *Neuron*, 87(6), 1215–1233.
1582 <https://doi.org/10.1016/j.neuron.2015.09.016>
- 1583 Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willsey, A. J.,
1584 Ercan-Sencicek, A. G., di Lullo, N. M., Parikshak, N. N., Stein, J. L., Walker, M. F., Ober,
1585 G. T., Teran, N. A., Song, Y., El-Fishawy, P., Murtha, R. C., Choi, M., Overton, J. D.,
1586 Bjornson, R. D., ... State, M. W. (2012). De novo mutations revealed by whole-exome
1587 sequencing are strongly associated with autism. *Nature*, 485(7397), 237–241.
1588 <https://doi.org/10.1038/nature10945>
- 1589 Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., de Rubeis, S., An, J. Y., Peng, M.,
1590 Collins, R., Grove, J., Klei, L., Stevens, C., Reichert, J., Mulhern, M. S., Artomov, M.,
1591 Gerges, S., Sheppard, B., Xu, X., Bhaduri, A., Norman, U., ... Buxbaum, J. D. (2020).
1592 Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional
1593 Changes in the Neurobiology of Autism. *Cell*, 180(3), 568-584.e23.
1594 <https://doi.org/10.1016/j.cell.2019.12.036>
- 1595 Saugier-Verber, P., Bonnet, C., Afenjar, A., Drouin-Garraud, V., Coubes, C., Fehrenbach, S.,
1596 Holder-Espinasse, M., Roume, J., Malan, V., Portnoi, M.-F., Jeanne, N., Baumann, C.,
1597 Héron, D., David, A., Gérard, M., Bonneau, D., Lacombe, D., Cormier-Daire, V., Billette de
1598 Villemeur, T., ... Bürglen, L. (2007). Heterogeneity of NSD1 alterations in 116 patients with
1599 Sotos syndrome. *Human Mutation*, 28(11), 1098–1107.
1600 <https://doi.org/10.1002/humu.20568>
- 1601 Smit, M. A., Tordoir, X., Gyapay, G., Cockett, N. E., Georges, M., & Charlier, C. (2005).
1602 BEGAIN: A novel imprinted gene that generates paternally expressed transcripts in a
1603 tissue- and promoter-specific manner in sheep. *Mammalian Genome*, 16(10), 801–814.
1604 <https://doi.org/10.1007/s00335-004-2415-z>
- 1605 Smith, A. M., LaValle, T. A., Shinawi, M., Ramakrishnan, S. M., Abel, H. J., Hill, C. A., Kirkland,
1606 N. M., Rettig, M. P., Helton, N. M., Heath, S. E., Ferraro, F., Chen, D. Y., Adak, S.,
1607 Semenkovich, C. F., Christian, D. L., Martin, J. R., Gabel, H. W., Miller, C. A., & Ley, T. J.
1608 (2021). Functional and epigenetic phenotypes of humans and mice with DNMT3A
1609 Overgrowth Syndrome. *Nature Communications*, 12(1). [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-021-24800-7)
1610 [021-24800-7](https://doi.org/10.1038/s41467-021-24800-7)
- 1611 Sollis, E., den Hoed, J., Quevedo, M., Estruch, S. B., Vino, A., W Dekkers, D. H., A Demmers,
1612 J. A., Poot, R., Deriziotis, P., & Fisher, S. E. (2022). Characterisation of the TBR1
1613 interactome: variants associated with neurodevelopmental disorders disrupt novel protein
1614 interactions. *Human Molecular Genetics*. <https://doi.org/10.1093/hmg/ddac311/6964999>
- 1615 Stejskal, E. O., & Tanner, J. E. (1965). Spin Diffusion Measurements: Spin Echoes in the
1616 Presence of a Time-Dependent Field Gradient. *The Journal of Chemical Physics*, 42(1),
1617 288–292. <https://doi.org/10.1063/1.1695690>
- 1618 Stroud, H., Su, S. C., Hrvatin, S., Greben, A. W., Renthal, W., Boxer, L. D., Nagy, M. A.,
1619 Hochbaum, D. R., Kinde, B., Gabel, H. W., & Greenberg, M. E. (2017). Early-Life Gene
1620 Expression in Neurons Modulates Lasting Epigenetic States. *Cell*, 171(5), 1151-1164.e16.
1621 <https://doi.org/10.1016/j.cell.2017.09.047>

- 1622 Swahari, V., Nakamura, A., Hollville, E., Stroud, H., Simon, J. M., Ptacek, T. S., Beck, M. v.,
1623 Flowers, C., Guo, J., Plestant, C., Liang, J., Kurtz, C. L., Kanke, M., Hammond, S. M., He,
1624 Y. W., Anton, E. S., Sethupathy, P., Moy, S. S., Greenberg, M. E., & Deshmukh, M. (2021).
1625 MicroRNA-29 is an essential regulator of brain maturation through regulation of CH
1626 methylation. *Cell Reports*, 35(1). <https://doi.org/10.1016/j.celrep.2021.108946>
- 1627 Tatton-Brown, K., Douglas, J., Coleman, K., Ve Baujat, G., Cole, T. R. P., Das, S., Horn, D.,
1628 Hughes, H. E., Temple, I. K., Faravelli, F., Waggoner, D., Türkmen, S., Cormier-Daire, V.,
1629 Irrthum, A., & Rahman, N. (2005). Genotype-Phenotype Associations in Sotos Syndrome:
1630 An Analysis of 266 Individuals with NSD1 Aberrations. In *Am. J. Hum. Genet* (Vol. 77).
- 1631 Tatton-Brown, K., Loveday, C., Yost, S., Clarke, M., Ramsay, E., Zachariou, A., Elliott, A.,
1632 Wylie, H., Ardisson, A., Rittinger, O., Stewart, F., Temple, I. K., Cole, T., Mahamdallie, S.,
1633 Seal, S., Ruark, E., & Rahman, N. (2017). Mutations in Epigenetic Regulation Genes Are a
1634 Major Cause of Overgrowth with Intellectual Disability. *American Journal of Human*
1635 *Genetics*, 100(5), 725–736. <https://doi.org/10.1016/j.ajhg.2017.03.010>
- 1636 Tatton-Brown, K., Seal, S., Ruark, E., Harmer, J., Ramsay, E., del Vecchio Duarte, S.,
1637 Zachariou, A., Hanks, S., O'Brien, E., Aksglaede, L., Baralle, D., Dabir, T., Gener, B.,
1638 Goudie, D., Homfray, T., Kumar, A., Pilz, D. T., Selicorni, A., Temple, I. K., ... Rahman, N.
1639 (2014). Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth
1640 syndrome with intellectual disability. *Nature Genetics*, 46(4), 385–388.
1641 <https://doi.org/10.1038/ng.2917>
- 1642 Tatton-Brown, K., Zachariou, A., Loveday, C., Renwick, A., Mahamdallie, S., Aksglaede, L.,
1643 Baralle, D., Barge-Schaapveld, D., Blyth, M., Bouma, M., Breckpot, J., Crabb, B., Dabir, T.,
1644 Cormier-Daire, V., Fauth, C., Fisher, R., Gener, B., Goudie, D., Homfray, T., ... Rahman,
1645 N. (2018). The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de
1646 novo constitutive DNMT3A variants [version 1; referees: 3 approved]. *Wellcome Open*
1647 *Research*, 3. <https://doi.org/10.12688/wellcomeopenres.14430.1>
- 1648 Tillotson, R., Cholewa-Waclaw, J., Chhatbar, K., Connelly, J. C., Kirschner, S. A., Webb, S.,
1649 Koerner, M. v., Selfridge, J., Kelly, D. A., de Sousa, D., Brown, K., Lyst, M. J., Kriaucionis,
1650 S., & Bird, A. (2021). Neuronal non-CG methylation is an essential target for MeCP2
1651 function. *Molecular Cell*, 81(6), 1260-1275.e12.
1652 <https://doi.org/10.1016/j.molcel.2021.01.011>
- 1653 Tovy, A., Reyes, J. M., Zhang, L., Huang, Y.-H., Rosas, C., Daquinag, A. C., Guzman, A.,
1654 Ramabadran, R., Chen, C.-W., Gu, T., Gupta, S., Ortinau, L., Park, D., Cox, A. R., Rau, R.
1655 E., Hartig, S. M., Kolonin, M. G., & Goodell, M. A. (2022). Constitutive loss of DNMT3A
1656 causes morbid obesity through misregulation of adipogenesis. *ELife*, 11(e72359).
1657 <https://doi.org/10.7554/eLife>
- 1658 Tovy, A., Rosas, C., Gaikwad, A. S., Medrano, G., Zhang, L., Reyes, J. M., Huang, Y. H.,
1659 Arakawa, T., Kurtz, K., Conneely, S. E., Guzman, A. G., Aguilar, R., Gao, A., Chen, C. W.,
1660 Kim, J. J., Carter, M. T., Lasa-Aranzasti, A., Valenzuela, I., van Maldergem, L., ... Rau, R.
1661 E. (2022). Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth
1662 Tatton-Brown-Rahman syndrome. *Haematologica*, 107(4), 887–898.
1663 <https://doi.org/10.3324/haematol.2021.278990>

- 1664 Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulovari, A., Coe, B. P., Gillentine, M. A., Wilfert,
1665 A. B., Perez-Jurado, L. A., Kvarnung, M., Sleyp, Y., Earl, R. K., Rosenfeld, J. A.,
1666 Geisheker, M. R., Han, L., Du, B., Barnett, C., Thompson, E., Shaw, M., ... Xia, K. (2020).
1667 Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders.
1668 *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-18723-y>
- 1669 Williams, A., Cooney, E., Segal, G., Narayanan, S., Morand, M., & Agadi, S. (2022). GABRG1
1670 variant as a potential novel cause of epileptic encephalopathy, hypotonia, and global
1671 developmental delay. *American Journal of Medical Genetics, Part A*.
1672 <https://doi.org/10.1002/ajmg.a.62969>
- 1673 Yao, I., Iida, J., Nishimura, W., & Hata, Y. (1996). Synaptic and Nuclear Localization of Brain-
1674 Enriched Guanylate Kinase-Associated Protein. In *The Journal of Neuroscience* (Vol. 22,
1675 Issue 13).
- 1676 Zhao, X. F., Kohen, R., Parent, R., Duan, Y., Fisher, G. L., Korn, M. J., Ji, L., Wan, G., Jin, J.,
1677 Püsichel, A. W., Dolan, D. F., Parent, J. M., Corfas, G., Murphy, G. G., & Giger, R. J.
1678 (2018). PlexinA2 Forward Signaling through Rap1 GTPases Regulates Dentate Gyrus
1679 Development and Schizophrenia-like Behaviors. *Cell Reports*, 22(2), 456–470.
1680 <https://doi.org/10.1016/j.celrep.2017.12.044>
- 1681



















